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I 
Purpose and Use of the Standards of Care
The World Professional Association for Transgender Health (WPATH)I is an international, 
multidisciplinary, professional association whose mission is to promote evidence-based care, 
education, research, advocacy, public policy, and respect for transgender health. The vision of 
WPATH is to bring together diverse professionals dedicated to developing best practices and 
supportive policies worldwide that promote health, research, education, respect, dignity, and 
equality for transsexual, transgender, and gender nonconforming people in all cultural settings.
One of the main functions of WPATH is to promote the highest standards of health care for 
individuals through the articulation of Standards of Care (SOC) for the Health of Transsexual, 
Transgender, and Gender Nonconforming People. The SOC are based on the best available science 
and expert professional consensus.II Most of the research and experience in this field comes from 
a North American and Western European perspective; thus, adaptations of the SOC to other parts 
of the world are necessary. Suggestions for ways of thinking about cultural relativity and cultural 
competence are included in this version of the SOC.
The overall goal of the SOC is to provide clinical guidance for health professionals to assist 
transsexual, transgender, and gender nonconforming people with safe and effective pathways to 
achieving lasting personal comfort with their gendered selves, in order to maximize their overall 
health, psychological well-being, and self-fulfillment. This assistance may include primary care, 
gynecologic and urologic care, reproductive options, voice and communication therapy, mental 
health services (e.g., assessment, counseling, psychotherapy), and hormonal and surgical 
treatments. While this is primarily a document for health professionals, the SOC may also be 
used by individuals, their families, and social institutions to understand how they can assist with 
promoting optimal health for members of this diverse population. 
WPATH recognizes that health is dependent upon not only good clinical care but also social and 
political climates that provide and ensure social tolerance, equality, and the full rights of citizenship. 
Health is promoted through public policies and legal reforms that promote tolerance and equity 
I Formerly the Harry Benjamin International Gender Dysphoria Association
II The Standards of Care (SOC), Version 7 represents a significant departure from previous versions. Changes in this version are based 
upon significant cultural shifts, advances in clinical knowledge, and appreciation of the many health care issues that can arise for 
transsexual, transgender, and gender nonconforming people beyond hormone therapy and surgery (Coleman, 2009a, b, c, d).
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for gender and sexual diversity and that eliminate prejudice, discrimination, and stigma. WPATH is 
committed to advocacy for these changes in public policies and legal reforms. 
The Standards of Care Are Flexible Clinical Guidelines 
The SOC are intended to be flexible in order to meet the diverse health care needs of transsexual, 
transgender, and gender nonconforming people. While flexible, they offer standards for promoting 
optimal health care and guiding the treatment of people experiencing gender dysphoria – broadly 
defined as discomfort or distress that is caused by a discrepancy between a person’s gender 
identity and that person’s sex assigned at birth (and the associated gender role and/or primary and 
secondary sex characteristics) (Fisk, 1974; Knudson, De Cuypere, & Bockting, 2010b).  
As in all previous versions of the SOC, the criteria put forth in this document for hormone therapy 
and surgical treatments for gender dysphoria are clinical guidelines; individual health professionals 
and programs may modify them. Clinical departures from the SOC may come about because of a 
patient’s unique anatomic, social, or psychological situation; an experienced health professional’s 
evolving method of handling a common situation; a research protocol; lack of resources in various 
parts of the world; or the need for specific harm reduction strategies. These departures should 
be recognized as such, explained to the patient, and documented through informed consent for 
quality patient care and legal protection. This documentation is also valuable for the accumulation 
of new data, which can be retrospectively examined to allow for health care – and the SOC – to 
evolve. 
The SOC articulate standards of care but also acknowledge the role of making informed choices 
and the value of harm reduction approaches. In addition, this version of the SOC recognizes and 
validates various expressions of gender that may not necessitate psychological, hormonal, or surgical 
treatments. Some patients who present for care will have made significant self-directed progress 
towards gender role changes, transition, or other resolutions regarding their gender identity or 
gender dysphoria. Other patients will require more intensive services. Health professionals can use 
the SOC to help patients consider the full range of health services open to them, in accordance with 
their clinical needs and goals for gender expression. 
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II  
Global Applicability of the Standards of Care
While the SOC are intended for worldwide use, WPATH acknowledges that much of the recorded 
clinical experience and knowledge in this area of health care is derived from North American 
and Western European sources. From place to place, both across and within nations, there are 
differences in all of the following: social attitudes towards transsexual, transgender, and gender 
nonconforming people; constructions of gender roles and identities; language used to describe 
different gender identities; epidemiology of gender dysphoria; access to and cost of treatment; 
therapies offered; number and type of professionals who provide care; and legal and policy issues 
related to this area of health care (Winter, 2009). 
It is impossible for the SOC to reflect all of these differences. In applying these standards to other 
cultural contexts, health professionals must be sensitive to these differences and adapt the SOC 
according to local realities. For example, in a number of cultures, gender nonconforming people 
are found in such numbers and living in such ways as to make them highly socially visible (Peletz, 
2006). In settings such as these, it is common for people to initiate a change in their gender 
expression and physical characteristics while in their teens, or even earlier. Many grow up and live 
in a social, cultural, and even linguistic context quite unlike that of Western cultures. Yet almost 
all experience prejudice (Peletz, 2006; Winter, 2009). In many cultures, social stigma towards 
gender nonconformity is widespread and gender roles are highly prescriptive (Winter et al., 2009). 
Gender nonconforming people in these settings are forced to be hidden, and therefore may lack 
opportunities for adequate health care (Winter, 2009).
The SOC are not intended to limit efforts to provide the best available care to all individuals. 
Health professionals throughout the world – even in areas with limited resources and training 
opportunities – can apply the many core principles that undergird the SOC. These principles 
include the following: Exhibit respect for patients with nonconforming gender identities (do not 
pathologize differences in gender identity or expression); provide care (or refer to knowledgeable 
colleagues) that affirms patients’ gender identities and reduces the distress of gender dysphoria, 
when present; become knowledgeable about the health care needs of transsexual, transgender, and 
gender nonconforming people, including the benefits and risks of treatment options for gender 
dysphoria; match the treatment approach to the specific needs of patients, particularly their goals 
for gender expression and need for relief from gender dysphoria; facilitate access to appropriate 
care; seek patients’ informed consent before providing treatment; offer continuity of care; and be 
prepared to support and advocate for patients within their families and communities (schools, 
workplaces, and other settings). 
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Terminology is culturally and time-dependent and is rapidly evolving. It is important to use 
respectful language in different places and times, and among different people. As the SOC are 
translated into other languages, great care must be taken to ensure that the meanings of terms 
are accurately translated. Terminology in English may not be easily translated into other languages, 
and vice versa. Some languages do not have equivalent words to describe the various terms within 
this document; hence, translators should be cognizant of the underlying goals of treatment and 
articulate culturally applicable guidance for reaching those goals. 
III 
The Difference Between Gender 
Nonconformity and Gender Dysphoria
Being Transsexual, Transgender, or Gender Nonconforming 
Is a Matter of Diversity, Not Pathology 
WPATH released a statement in May 2010 urging the de-psychopathologization of gender 
nonconformity worldwide (WPATH Board of Directors, 2010). This statement noted that “the 
expression of gender characteristics, including identities, that are not stereotypically associated 
with one’s assigned sex at birth is a common and culturally-diverse human phenomenon [that] 
should not be judged as inherently pathological or negative.”
Unfortunately, there is stigma attached to gender nonconformity in many societies around the 
world. Such stigma can lead to prejudice and discrimination, resulting in “minority stress” (I. H. 
Meyer, 2003). Minority stress is unique (additive to general stressors experienced by all people), 
socially based, and chronic, and may make transsexual, transgender, and gender nonconforming 
individuals more vulnerable to developing mental health concerns such as anxiety and depression 
(Institute of Medicine, 2011). In addition to prejudice and discrimination in society at large, stigma 
can contribute to abuse and neglect in one’s relationships with peers and family members, which 
in turn can lead to psychological distress. However, these symptoms are socially induced and are 
not inherent to being transsexual, transgender, or gender nonconforming. 
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Gender Nonconformity Is Not the Same as Gender Dysphoria 
Gender nonconformity refers to the extent to which a person’s gender identity, role, or expression 
differs from the cultural norms prescribed for people of a particular sex (Institute of Medicine, 
2011). Gender dysphoria refers to discomfort or distress that is caused by a discrepancy between 
a person’s gender identity and that person’s sex assigned at birth (and the associated gender role 
and/or primary and secondary sex characteristics) (Fisk, 1974; Knudson, De Cuypere, & Bockting, 
2010b). Only some gender nonconforming people experience gender dysphoria at some point in 
their lives.
Treatment is available to assist people with such distress to explore their gender identity and find a 
gender role that is comfortable for them (Bockting & Goldberg, 2006). Treatment is individualized: 
What helps one person alleviate gender dysphoria might be very different from what helps 
another person. This process may or may not involve a change in gender expression or body 
modifications. Medical treatment options include, for example, feminization or masculinization 
of the body through hormone therapy and/or surgery, which are effective in alleviating gender 
dysphoria and are medically necessary for many people. Gender identities and expressions are 
diverse, and hormones and surgery are just two of many options available to assist people with 
achieving comfort with self and identity. 
Gender dysphoria can in large part be alleviated through treatment (Murad et al., 2010). Hence, 
while transsexual, transgender, and gender nonconforming people may experience gender 
dysphoria at some points in their lives, many individuals who receive treatment will find a gender 
role and expression that is comfortable for them, even if these differ from those associated with 
their sex assigned at birth, or from prevailing gender norms and expectations. 
Diagnoses Related to Gender Dysphoria
Some people experience gender dysphoria at such a level that the distress meets criteria for a 
formal diagnosis that might be classified as a mental disorder. Such a diagnosis is not a license for 
stigmatization or for the deprivation of civil and human rights. Existing classification systems such 
as the Diagnostic Statistical Manual of Mental Disorders (DSM) (American Psychiatric Association, 
2000) and the International Classification of Diseases (ICD) (World Health Organization, 2007) 
define hundreds of mental disorders that vary in onset, duration, pathogenesis, functional disability, 
and treatability. All of these systems attempt to classify clusters of symptoms and conditions, not 
the individuals themselves. A disorder is a description of something with which a person might 
struggle, not a description of the person or the person’s identity. 
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Thus, transsexual, transgender, and gender nonconforming individuals are not inherently 
disordered. Rather, the distress of gender dysphoria, when present, is the concern that might be 
diagnosable and for which various treatment options are available. The existence of a diagnosis for 
such dysphoria often facilitates access to health care and can guide further research into effective 
treatments.
Research is leading to new diagnostic nomenclatures, and terms are changing in both the DSM 
(Cohen-Kettenis & Pfäfflin, 2010; Knudson, De Cuypere, & Bockting, 2010b; Meyer-Bahlburg, 2010; 
Zucker, 2010) and the ICD. For this reason, familiar terms are employed in the SOC and definitions 
are provided for terms that may be emerging. Health professionals should refer to the most current 
diagnostic criteria and appropriate codes to apply in their practice areas.
IV  
Epidemiologic Considerations
Formal epidemiologic studies on the incidenceIII and prevalenceIV of transsexualism specifically or 
transgender and gender nonconforming identities in general have not been conducted, and efforts 
to achieve realistic estimates are fraught with enormous difficulties (Institute of Medicine, 2011; 
Zucker & Lawrence, 2009). Even if epidemiologic studies established that a similar proportion of 
transsexual, transgender, or gender nonconforming people existed all over the world, it is likely that 
cultural differences from one country to another would alter both the behavioral expressions of 
different gender identities and the extent to which gender dysphoria – distinct from one’s gender 
identity – is actually occurring in a population. While in most countries, crossing normative gender 
boundaries generates moral censure rather than compassion, there are examples in certain cultures 
of gender nonconforming behaviors (e.g., in spiritual leaders) that are less stigmatized and even 
revered (Besnier, 1994; Bolin, 1988; Chiñas, 1995; Coleman, Colgan, & Gooren, 1992; Costa & 
Matzner, 2007; Jackson & Sullivan, 1999; Nanda, 1998; Taywaditep, Coleman, & Dumronggittigule, 
1997). 
For various reasons, researchers who have studied incidence and prevalence have tended to focus 
on the most easily counted subgroup of gender nonconforming individuals: transsexual individuals 
who experience gender dysphoria and who present for gender-transition-related care at specialist 
gender clinics (Zucker & Lawrence, 2009). Most studies have been conducted in European 
III incidence—the number of new cases arising in a given period (e.g., a year)
IV prevalence—the number of individuals having a condition, divided by the number of people in the general population
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countries such as Sweden (Wålinder, 1968, 1971), the United Kingdom (Hoenig & Kenna, 1974), 
the Netherlands (Bakker, Van Kesteren, Gooren, & Bezemer, 1993; Eklund, Gooren, & Bezemer, 
1988; van Kesteren, Gooren, & Megens, 1996), Germany (Weitze & Osburg, 1996), and Belgium 
(De Cuypere et al., 2007). One was conducted in Singapore (Tsoi, 1988). 
De Cuypere and colleagues (2007) reviewed such studies, as well as conducted their own. Together, 
those studies span 39 years. Leaving aside two outlier findings from Pauly in 1965 and Tsoi in 1988, 
ten studies involving eight countries remain. The prevalence figures reported in these ten studies 
range from 1:11,900 to 1:45,000 for male-to-female individuals (MtF) and 1:30,400 to 1:200,000 
for female-to-male (FtM) individuals. Some scholars have suggested that the prevalence is much 
higher, depending on the methodology used in the research (e.g., Olyslager & Conway, 2007). 
Direct comparisons across studies are impossible, as each differed in their data collection methods 
and in their criteria for documenting a person as transsexual (e.g., whether or not a person had 
undergone genital reconstruction, versus had initiated hormone therapy, versus had come to the 
clinic seeking medically-supervised transition services). The trend appears to be towards higher 
prevalence rates in the more recent studies, possibly indicating increasing numbers of people 
seeking clinical care. Support for this interpretation comes from research by Reed and colleagues 
(2009), who reported a doubling of the numbers of people accessing care at gender clinics in the 
United Kingdom every five or six years. Similarly, Zucker and colleagues (2008) reported a four- to 
five-fold increase in child and adolescent referrals to their Toronto, Canada clinic over a 30-year 
period.
The numbers yielded by studies such as these can be considered minimum estimates at best. The 
published figures are mostly derived from clinics where patients met criteria for severe gender 
dysphoria and had access to health care at those clinics. These estimates do not take into account 
that treatments offered in a particular clinic setting might not be perceived as affordable, useful, or 
acceptable by all self-identified gender dysphoric individuals in a given area. By counting only those 
people who present at clinics for a specific type of treatment, an unspecified number of gender 
dysphoric individuals are overlooked. 
Other clinical observations (not yet firmly supported by systematic study) support the likelihood of a 
higher prevalence of gender dysphoria: (i) Previously unrecognized gender dysphoria is occasionally 
diagnosed when patients are seen with anxiety, depression, conduct disorder, substance abuse, 
dissociative identity disorders, borderline personality disorder, sexual disorders, and disorders of 
sex development (Cole, O’Boyle, Emory, & Meyer III, 1997). (ii) Some crossdressers, drag queens/
kings or female/male impersonators, and gay and lesbian individuals may be experiencing gender 
dysphoria (Bullough & Bullough, 1993). (iii)  The intensity of some people’s gender dysphoria 
fluctuates below and above a clinical threshold (Docter, 1988). (iv) Gender nonconformity among 
FtM individuals tends to be relatively invisible in many cultures, particularly to Western health 
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professionals and researchers who have conducted most of the studies on which the current 
estimates of prevalence and incidence are based (Winter, 2009).
Overall, the existing data should be considered a starting point, and health care would benefit from 
more rigorous epidemiologic study in different locations worldwide.
V 
Overview of Therapeutic Approaches for 
Gender Dysphoria
Advancements in the Knowledge and 
Treatment of Gender Dysphoria 
In the second half of the 20th century, awareness of the phenomenon of gender dysphoria increased 
when health professionals began to provide assistance to alleviate gender dysphoria by supporting 
changes in primary and secondary sex characteristics through hormone therapy and surgery, along 
with a change in gender role. Although Harry Benjamin already acknowledged a spectrum of 
gender nonconformity (Benjamin, 1966), the initial clinical approach largely focused on identifying 
who was an appropriate candidate for sex reassignment to facilitate a physical change from male 
to female or female to male as completely as possible (e.g., Green & Fleming, 1990; Hastings, 
1974). This approach was extensively evaluated and proved to be highly effective. Satisfaction 
rates across studies ranged from 87% of MtF patients to 97% of FtM patients (Green & Fleming, 
1990), and regrets were extremely rare (1-1.5% of MtF patients and <1% of FtM patients; Pfäfflin, 
1993). Indeed, hormone therapy and surgery have been found to be medically necessary to alleviate 
gender dysphoria in many people (American Medical Association, 2008; Anton, 2009; The World 
Professional Association for Transgender Health, 2008).
As the field matured, health professionals recognized that while many individuals need both 
hormone therapy and surgery to alleviate their gender dysphoria, others need only one of these 
treatment options and some need neither (Bockting & Goldberg, 2006; Bockting, 2008; Lev, 2004). 
Often with the help of psychotherapy, some individuals integrate their trans- or cross-gender 
feelings into the gender role they were assigned at birth and do not feel the need to feminize or 
masculinize their body. For others, changes in gender role and expression are sufficient to alleviate 
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gender dysphoria. Some patients may need hormones, a possible change in gender role, but not 
surgery; others may need a change in gender role along with surgery, but not hormones. In other 
words, treatment for gender dysphoria has become more individualized. 
As a generation of transsexual, transgender, and gender nonconforming individuals has come of 
age – many of whom have benefitted from different therapeutic approaches – they have become 
more visible as a community and demonstrated considerable diversity in their gender identities, 
roles, and expressions. Some individuals describe themselves not as gender nonconforming but as 
unambiguously cross-sexed (i.e., as a member of the other sex; Bockting, 2008). Other individuals 
affirm their unique gender identity and no longer consider themselves to be either male or female 
(Bornstein, 1994; Kimberly, 1997; Stone, 1991; Warren, 1993). Instead, they may describe their 
gender identity in specific terms such as transgender, bigender, or genderqueer, affirming their 
unique experiences that may transcend a male/female binary understanding of gender (Bockting, 
2008; Ekins & King, 2006; Nestle, Wilchins, & Howell, 2002). They may not experience their process 
of identity affirmation as a “transition,” because they never fully embraced the gender role they were 
assigned at birth or because they actualize their gender identity, role, and expression in a way that 
does not involve a change from one gender role to another. For example, some youth identifying as 
genderqueer have always experienced their gender identity and role as such (genderqueer). Greater 
public visibility and awareness of gender diversity (Feinberg, 1996) has further expanded options 
for people with gender dysphoria to actualize an identity and find a gender role and expression that 
are comfortable for them.
Health professionals can assist gender dysphoric individuals with affirming their gender identity, 
exploring different options for expression of that identity, and making decisions about medical 
treatment options for alleviating gender dysphoria.
Options for Psychological and Medical 
Treatment of Gender Dysphoria 
For individuals seeking care for gender dysphoria, a variety of therapeutic options can be considered. 
The number and type of interventions applied and the order in which these take place may differ 
from person to person (e.g., Bockting, Knudson, & Goldberg, 2006; Bolin, 1994; Rachlin, 1999; 
Rachlin, Green, & Lombardi, 2008; Rachlin, Hansbury, & Pardo, 2010). Treatment options include 
the following:
•	Changes in gender expression and role (which may involve living part time or full time in 
another gender role, consistent with one’s gender identity);
•	Hormone therapy to feminize or masculinize the body;
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•	Surgery to change primary and/or secondary sex characteristics (e.g., breasts/chest, external 
and/or internal genitalia, facial features, body contouring);
•	Psychotherapy (individual, couple, family, or group) for purposes such as exploring gender 
identity, role, and expression; addressing the negative impact of gender dysphoria and stigma 
on mental health; alleviating internalized transphobia; enhancing social and peer support; 
improving body image; or promoting resilience. 
Options for Social Support and Changes in Gender Expression
In addition (or as an alternative) to the psychological and medical treatment options described 
above, other options can be considered to help alleviate gender dysphoria, for example: 
•	In person and online peer support resources, groups, or community organizations that pro-
vide avenues for social support and advocacy;
•	In person and online support resources for families and friends;
•	Voice and communication therapy to help individuals develop verbal and non-verbal commu-
nication skills that facilitate comfort with their gender identity; 
•	Hair removal through electrolysis, laser treatment, or waxing;
•	Breast binding or padding, genital tucking or penile prostheses, padding of hips or buttocks;
•	Changes in name and gender marker on identity documents.
VI  
Assessment and Treatment of Children and 
Adolescents with Gender Dysphoria 
There are a number of differences in the phenomenology, developmental course, and treatment 
approaches for gender dysphoria in children, adolescents, and adults. In children and adolescents, 
a rapid and dramatic developmental process (physical, psychological, and sexual) is involved and 
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there is greater fluidity and variability in outcomes, particular in prepubertal children. Accordingly, 
this section of the SOC offers specific clinical guidelines for the assessment and treatment of 
gender dysphoric children and adolescents.
Differences between Children and 
Adolescents with Gender Dysphoria
An important difference between gender dysphoric children and adolescents is in the proportion for 
whom dysphoria persists into adulthood. Gender dysphoria during childhood does not inevitably 
continue into adulthood.V Rather, in follow-up studies of prepubertal children (mainly boys) who 
were referred to clinics for assessment of gender dysphoria, the dysphoria persisted into adulthood 
for only 6-23% of children (Cohen-Kettenis, 2001; Zucker & Bradley, 1995). Boys in these studies 
were more likely to identify as gay in adulthood than as transgender (Green, 1987; Money & Russo, 
1979; Zucker & Bradley, 1995; Zuger, 1984). Newer studies, also including girls, showed a 12-
27% persistence rate of gender dysphoria into adulthood (Drummond, Bradley, Peterson-Badali, & 
Zucker, 2008; Wallien & Cohen-Kettenis, 2008). 
In contrast, the persistence of gender dysphoria into adulthood appears to be much higher for 
adolescents. No formal prospective studies exist. However, in a follow-up study of 70 adolescents 
who were diagnosed with gender dysphoria and given puberty suppressing hormones, all continued 
with actual sex reassignment, beginning with feminizing/masculinizing hormone therapy (de Vries, 
Steensma, Doreleijers, & Cohen-Kettenis, 2010). 
Another difference between gender dysphoric children and adolescents is in the sex ratios for each 
age group. In clinically-referred, gender dysphoric children under age 12, the male/female ratio 
ranges from 6:1 to 3:1 (Zucker, 2004). In clinically referred, gender dysphoric adolescents older 
than age 12, the male/female ratio is close to 1:1 (Cohen-Kettenis & Pfäfflin, 2003). 
As discussed in section IV and by Zucker and Lawrence (2009), formal epidemiologic studies on 
gender dysphoria – in children, adolescents, and adults – are lacking. Additional research is needed 
to refine estimates of its prevalence and persistence in different populations worldwide. 
V Gender nonconforming behaviors in children may continue into adulthood, but such behaviors are not necessarily indicative of 
gender dysphoria and a need for treatment. As described in section III, gender dysphoria is not synonymous with diversity in 
gender expression.
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Phenomenology in Children
Children as young as age two may show features that could indicate gender dysphoria. They may 
express a wish to be of the other sex and be unhappy about their physical sex characteristics and 
functions. In addition, they may prefer clothes, toys, and games that are commonly associated 
with the other sex and prefer playing with other-sex peers. There appears to be heterogeneity in 
these features: Some children demonstrate extremely gender nonconforming behavior and wishes, 
accompanied by persistent and severe discomfort with their primary sex characteristics. In other 
children, these characteristics are less intense or only partially present (Cohen-Kettenis et al., 2006; 
Knudson, De Cuypere, & Bockting, 2010a). 
It is relatively common for gender dysphoric children to have co-existing internalizing disorders 
such as anxiety and depression (Cohen-Kettenis, Owen, Kaijser, Bradley, & Zucker, 2003; Wallien, 
Swaab, & Cohen-Kettenis, 2007; Zucker, Owen, Bradley, & Ameeriar, 2002). The prevalence of 
autism spectrum disorders seems to be higher in clinically-referred, gender dysphoric children than 
in the general population (de Vries, Noens, Cohen-Kettenis, van Berckelaer-Onnes, & Doreleijers, 
2010). 
Phenomenology in Adolescents
In most children, gender dysphoria will disappear before, or early in, puberty. However, in some 
children these feelings will intensify and body aversion will develop or increase as they become 
adolescents and their secondary sex characteristics develop (Cohen-Kettenis, 2001; Cohen-Kettenis 
& Pfäfflin, 2003; Drummond et al., 2008; Wallien & Cohen-Kettenis, 2008; Zucker & Bradley, 1995). 
Data from one study suggest that more extreme gender nonconformity in childhood is associated 
with persistence of gender dysphoria into late adolescence and early adulthood (Wallien & Cohen-
Kettenis, 2008). Yet many adolescents and adults presenting with gender dysphoria do not report 
a history of childhood gender nonconforming behaviors (Docter, 1988; Landén, Wålinder, & 
Lundström, 1998). Therefore, it may come as a surprise to others (parents, other family members, 
friends, and community members) when a youth’s gender dysphoria first becomes evident in 
adolescence. 
Adolescents who experience their primary and/or secondary sex characteristics and their sex 
assigned at birth as inconsistent with their gender identity may be intensely distressed about it. 
Many, but not all, gender dysphoric adolescents have a strong wish for hormones and surgery. 
Increasing numbers of adolescents have already started living in their desired gender role upon 
entering high school (Cohen-Kettenis & Pfäfflin, 2003). 
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Among adolescents who are referred to gender identity clinics, the number considered eligible for 
early medical treatment – starting with GnRH analogues to suppress puberty in the first Tanner 
stages – differs among countries and centers. Not all clinics offer puberty suppression. If such 
treatment is offered, the pubertal stage at which adolescents are allowed to start varies from Tanner 
stage 2 to stage 4 (Delemarre-van de Waal & Cohen-Kettenis, 2006; Zucker et al., in press). The 
percentages of treated adolescents are likely influenced by the organization of health care, insurance 
aspects, cultural differences, opinions of health professionals, and diagnostic procedures offered 
in different settings.
Inexperienced clinicians may mistake indications of gender dysphoria for delusions. 
Phenomenologically, there is a qualitative difference between the presentation of gender dysphoria 
and the presentation of delusions or other psychotic symptoms. The vast majority of children and 
adolescents with gender dysphoria are not suffering from underlying severe psychiatric illness such 
as psychotic disorders (Steensma, Biemond, de Boer, & Cohen-Kettenis, published online ahead 
of print January 7, 2011). 
It is more common for adolescents with gender dysphoria to have co-existing internalizing 
disorders such as anxiety and depression, and/or externalizing disorders such as oppositional 
defiant disorder (de Vries et al., 2010). As in children, there seems to be a higher prevalence of 
autistic spectrum disorders in clinically-referred, gender dysphoric adolescents than in the general 
adolescent population (de Vries et al., 2010).
Competency of Mental Health Professionals Working 
with Children or Adolescents with Gender Dysphoria 
The following are recommended minimum credentials for mental health professionals who assess, 
refer, and offer therapy to children and adolescents presenting with gender dysphoria: 
1. Meet the competency requirements for mental health professionals working with adults, as 
outlined in section VII;
2. Trained in childhood and adolescent developmental psychopathology;
3. Competent in diagnosing and treating the ordinary problems of children and adolescents. 
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Roles of Mental Health Professionals Working with 
Children and Adolescents with Gender Dysphoria 
The roles of mental health professionals working with gender dysphoric children and adolescents 
may include the following:
1. Directly assess gender dysphoria in children and adolescents (see general guidelines for as-
sessment, below).
2. Provide family counseling and supportive psychotherapy to assist children and adolescents 
with exploring their gender identity, alleviating distress related to their gender dysphoria, and 
ameliorating any other psychosocial difficulties.
3. Assess and treat any co-existing mental health concerns of children or adolescents (or refer to 
another mental health professional for treatment). Such concerns should be addressed as part 
of the overall treatment plan.
4. Refer adolescents for additional physical interventions (such as puberty suppressing hor-
mones) to alleviate gender dysphoria. The referral should include documentation of an as-
sessment of gender dysphoria and mental health, the adolescent’s eligibility for physical inter-
ventions (outlined below), the mental health professional’s relevant expertise, and any other 
information pertinent to the youth’s health and referral for specific treatments. 
5. Educate and advocate on behalf of gender dysphoric children, adolescents, and their families 
in their community (e.g., day care centers, schools, camps, other organizations). This is par-
ticularly important in light of evidence that children and adolescents who do not conform to 
socially prescribed gender norms may experience harassment in school (Grossman, D’Augelli, 
& Salter, 2006; Grossman, D’Augelli, Howell, & Hubbard, 2006; Sausa, 2005), putting them at 
risk for social isolation, depression, and other negative sequelae (Nuttbrock et al., 2010).
6. Provide children, youth, and their families with information and referral for peer support, such 
as support groups for parents of gender nonconforming and transgender children (Gold & 
MacNish, 2011; Pleak, 1999; Rosenberg, 2002).
Assessment and psychosocial interventions for children and adolescents are often provided 
within a multi-disciplinary gender identity specialty service. If such a multidisciplinary service is 
not available, a mental health professional should provide consultation and liaison arrangements 
with a pediatric endocrinologist for the purpose of assessment, education, and involvement in any 
decisions about physical interventions.
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Psychological Assessment of Children and Adolescents
When assessing children and adolescents who present with gender dysphoria, mental health 
professionals should broadly conform to the following guidelines:
1. Mental health professionals should not dismiss or express a negative attitude towards noncon-
forming gender identities or indications of gender dysphoria. Rather, they should acknowledge 
the presenting concerns of children, adolescents, and their families; offer a thorough assess-
ment for gender dysphoria and any co-existing mental health concerns; and educate clients 
and their families about therapeutic options, if needed. Acceptance, and alleviation of secrecy, 
can bring considerable relief to gender dysphoric children/adolescents and their families.
2. Assessment of gender dysphoria and mental health should explore the nature and characteris-
tics of a child’s or adolescent’s gender identity. A psychodiagnostic and psychiatric assessment 
– covering the areas of emotional functioning, peer and other social relationships, and intel-
lectual functioning/school achievement – should be performed. Assessment should include 
an evaluation of the strengths and weaknesses of family functioning. Emotional and behavioral 
problems are relatively common, and unresolved issues in a child’s or youth’s environment 
may be present (de Vries, Doreleijers, Steensma, & Cohen-Kettenis, 2011; Di Ceglie & Thüm-
mel, 2006; Wallien et al., 2007).
3. For adolescents, the assessment phase should also be used to inform youth and their families 
about the possibilities and limitations of different treatments. This is necessary for informed 
consent, but also important for assessment. The way that adolescents respond to information 
about the reality of sex reassignment can be diagnostically informative. Correct information 
may alter a youth’s desire for certain treatment, if the desire was based on unrealistic expecta-
tions of its possibilities. 
Psychological and Social Interventions 
for Children and Adolescents
When supporting and treating children and adolescents with gender dysphoria, health professionals 
should broadly conform to the following guidelines:
1. Mental health professionals should help families to have an accepting and nurturing response 
to the concerns of their gender dysphoric child or adolescent. Families play an important role in 
the psychological health and well-being of youth (Brill & Pepper, 2008; Lev, 2004). This also ap-
plies to peers and mentors from the community, who can be another source of social support. 
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2. Psychotherapy should focus on reducing a child’s or adolescent’s distress related to the gender 
dysphoria and on ameliorating any other psychosocial difficulties. For youth pursuing sex reas-
signment, psychotherapy may focus on supporting them before, during, and after reassign-
ment. Formal evaluations of different psychotherapeutic approaches for this situation have not 
been published, but several counseling methods have been described (Cohen-Kettenis, 2006; 
de Vries, Cohen-Kettenis, & Delemarre-van de Waal, 2006; Di Ceglie & Thümmel, 2006; Hill, 
Menvielle, Sica, & Johnson, 2010; Malpas, in press; Menvielle & Tuerk, 2002; Rosenberg, 2002; 
Vanderburgh, 2009; Zucker, 2006).
 Treatment aimed at trying to change a person’s gender identity and expression to become 
more congruent with sex assigned at birth has been attempted in the past without success 
(Gelder & Marks, 1969; Greenson, 1964), particularly in the long term (Cohen-Kettenis & Kui-
per, 1984; Pauly, 1965). Such treatment is no longer considered ethical. 
3. Families should be supported in managing uncertainty and anxiety about their child’s or ado-
lescent’s psychosexual outcomes and in helping youth to develop a positive self-concept.
4. Mental health professionals should not impose a binary view of gender. They should give 
ample room for clients to explore different options for gender expression. Hormonal or surgi-
cal interventions are appropriate for some adolescents, but not for others.
5. Clients and their families should be supported in making difficult decisions regarding the ex-
tent to which clients are allowed to express a gender role that is consistent with their gender 
identity, as well as the timing of changes in gender role and possible social transition. For 
example, a client might attend school while undergoing social transition only partly (e.g., by 
wearing clothing and having a hairstyle that reflects gender identity) or completely (e.g., by also 
using a name and pronouns congruent with gender identity). Difficult issues include whether 
and when to inform other people of the client’s situation, and how others in their lives might 
respond.
6. Health professionals should support clients and their families as educators and advocates in 
their interactions with community members and authorities such as teachers, school boards, 
and courts. 
7. Mental health professionals should strive to maintain a therapeutic relationship with gender 
nonconforming children/adolescents and their families throughout any subsequent social 
changes or physical interventions. This ensures that decisions about gender expression and 
the treatment of gender dysphoria are thoughtfully and recurrently considered. The same rea-
soning applies if a child or adolescent has already socially changed gender role prior to being 
seen by a mental health professional. 
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Social Transition in Early Childhood
Some children state that they want to make a social transition to a different gender role long before 
puberty. For some children, this may reflect an expression of their gender identity. For others, this 
could be motivated by other forces. Families vary in the extent to which they allow their young 
children to make a social transition to another gender role. Social transitions in early childhood 
do occur within some families with early success. This is a controversial issue, and divergent 
views are held by health professionals. The current evidence base is insufficient to predict the 
long-term outcomes of completing a gender role transition during early childhood. Outcomes 
research with children who completed early social transitions would greatly inform future clinical 
recommendations. 
Mental health professionals can help families to make decisions regarding the timing and process 
of any gender role changes for their young children. They should provide information and help 
parents to weigh the potential benefits and challenges of particular choices. Relevant in this 
respect are the previously described relatively low persistence rates of childhood gender dysphoria 
(Drummond et al., 2008; Wallien & Cohen-Kettenis, 2008). A change back to the original gender 
role can be highly distressing and even result in postponement of this second social transition 
on the child’s part (Steensma & Cohen-Kettenis, 2011). For reasons such as these, parents may 
want to present this role change as an exploration of living in another gender role, rather than an 
irreversible situation. Mental health professionals can assist parents in identifying potential in-
between solutions or compromises (e.g., only when on vacation). It is also important that parents 
explicitly let the child know that there is a way back. 
Regardless of a family’s decisions regarding transition (timing, extent), professionals should 
counsel and support them as they work through the options and implications. If parents do not 
allow their young child to make a gender role transition, they may need counseling to assist them 
with meeting their child’s needs in a sensitive and nurturing way, ensuring that the child has 
ample possibilities to explore gender feelings and behavior in a safe environment. If parents do 
allow their young child to make a gender role transition, they may need counseling to facilitate a 
positive experience for their child. For example, they may need support in using correct pronouns, 
maintaining a safe and supportive environment for their transitioning child (e.g., in school, peer 
group settings), and communicating with other people in their child’s life. In either case, as a child 
nears puberty, further assessment may be needed as options for physical interventions become 
relevant.
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Physical Interventions for Adolescents 
Before any physical interventions are considered for adolescents, extensive exploration of 
psychological, family, and social issues should be undertaken, as outlined above. The duration of 
this exploration may vary considerably depending on the complexity of the situation. 
Physical interventions should be addressed in the context of adolescent development. Some identity 
beliefs in adolescents may become firmly held and strongly expressed, giving a false impression 
of irreversibility. An adolescent’s shift towards gender conformity can occur primarily to please the 
parents and may not persist or reflect a permanent change in gender dysphoria (Hembree et al., 
2009; Steensma et al., published online ahead of print January 7, 2011). 
Physical interventions for adolescents fall into three categories or stages (Hembree et al., 2009):
1. Fully reversible interventions. These involve the use of GnRH analogues to suppress estrogen 
or testosterone production and consequently delay the physical changes of puberty. Alterna-
tive treatment options include progestins (most commonly medroxyprogesterone) or other 
medications (such as spironolactone) that decrease the effects of androgens secreted by the 
testicles of adolescents who are not receiving GnRH analogues. Continuous oral contracep-
tives (or depot medroxyprogesterone) may be used to suppress menses.
2. Partially reversible interventions. These include hormone therapy to masculinize or feminize the 
body. Some hormone-induced changes may need reconstructive surgery to reverse the effect 
(e.g., gynaecomastia caused by estrogens), while other changes are not reversible (e.g., deep-
ening of the voice caused by testosterone).
3. Irreversible interventions . These are surgical procedures.
A staged process is recommended to keep options open through the first two stages. Moving from 
one stage to another should not occur until there has been adequate time for adolescents and their 
parents to assimilate fully the effects of earlier interventions. 
Fully Reversible Interventions
Adolescents may be eligible for puberty suppressing hormones as soon as pubertal changes have 
begun. In order for adolescents and their parents to make an informed decision about pubertal 
delay, it is recommended that adolescents experience the onset of puberty to at least Tanner 
Stage 2. Some children may arrive at this stage at very young ages (e.g., 9 years of age). Studies 
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evaluating this approach have only included children who were at least 12 years of age (Cohen-
Kettenis, Schagen, Steensma, de Vries, & Delemarre-van de Waal, 2011; de Vries, Steensma et al., 
2010; Delemarre-van de Waal, van Weissenbruch, & Cohen Kettenis, 2004; Delemarre-van de Waal 
& Cohen-Kettenis, 2006). 
Two goals justify intervention with puberty suppressing hormones: (i) their use gives adolescents 
more time to explore their gender nonconformity and other developmental issues; and (ii) their 
use may facilitate transition by preventing the development of sex characteristics that are difficult 
or impossible to reverse if adolescents continue on to pursue sex reassignment. 
Puberty suppression may continue for a few years, at which time a decision is made to either 
discontinue all hormone therapy or transition to a feminizing/masculinizing hormone regimen. 
Pubertal suppression does not inevitably lead to social transition or to sex reassignment. 
Criteria for puberty suppressing hormones
In order for adolescents to receive puberty suppressing hormones, the following minimum criteria 
must be met:
1. The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity 
or gender dysphoria (whether suppressed or expressed);
2. Gender dysphoria emerged or worsened with the onset of puberty; 
3. Any co-existing psychological, medical, or social problems that could interfere with treatment 
(e.g., that may compromise treatment adherence) have been addressed, such that the adoles-
cent’s situation and functioning are stable enough to start treatment;
4. The adolescent has given informed consent and, particularly when the adolescent has not 
reached the age of medical consent, the parents or other caretakers or guardians have con-
sented to the treatment and are involved in supporting the adolescent throughout the treat-
ment process. 
Regimens, monitoring, and risks for puberty suppression
For puberty suppression, adolescents with male genitalia should be treated with GnRH analogues, 
which stop luteinizing hormone secretion and therefore testosterone secretion. Alternatively, 
they may be treated with progestins (such as medroxyprogesterone) or with other medications 
that block testosterone secretion and/or neutralize testosterone action. Adolescents with female 
genitalia should be treated with GnRH analogues, which stop the production of estrogens and 
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progesterone. Alternatively, they may be treated with progestins (such as medroxyprogesterone). 
Continuous oral contraceptives (or depot medroxyprogesterone) may be used to suppress menses. 
In both groups of adolescents, use of GnRH analogues is the preferred treatment (Hembree et al., 
2009), but their high cost is prohibitive for some patients.
During pubertal suppression, an adolescent’s physical development should be carefully monitored 
– preferably by a pediatric endocrinologist – so that any necessary interventions can occur (e.g., to 
establish an adequate gender appropriate height, to improve iatrogenic low bone mineral density) 
(Hembree et al., 2009). 
Early use of puberty suppressing hormones may avert negative social and emotional consequences 
of gender dysphoria more effectively than their later use would. Intervention in early adolescence 
should be managed with pediatric endocrinological advice, when available. Adolescents with male 
genitalia who start GnRH analogues early in puberty should be informed that this could result in 
insufficient penile tissue for penile inversion vaginoplasty techniques (alternative techniques, such 
as the use of a skin graft or colon tissue, are available).
Neither puberty suppression nor allowing puberty to occur is a neutral act. On the one hand, 
functioning in later life can be compromised by the development of irreversible secondary sex 
characteristics during puberty and by years spent experiencing intense gender dysphoria. On the 
other hand, there are concerns about negative physical side effects of GnRH analogue use (e.g., on 
bone development and height). Although the very first results of this approach (as assessed for 
adolescents followed over 10 years) are promising (Cohen-Kettenis et al., 2011; Delemarre-van 
de Waal & Cohen-Kettenis, 2006), the long-term effects can only be determined when the earliest-
treated patients reach the appropriate age. 
Partially Reversible Interventions
Adolescents may be eligible to begin feminizing/masculinizing hormone therapy, preferably with 
parental consent. In many countries, 16-year-olds are legal adults for medical decision-making 
and do not require parental consent. Ideally, treatment decisions should be made among the 
adolescent, the family, and the treatment team. 
Regimens for hormone therapy in gender dysphoric adolescents differ substantially from those 
used in adults (Hembree et al., 2009). The hormone regimens for youth are adapted to account for 
the somatic, emotional, and mental development that occurs throughout adolescence (Hembree 
et al., 2009).  
21
The Standards of Care 
7TH VERSION
World Professional Association for Transgender Health
Irreversible Interventions
Genital surgery should not be carried out until (i) patients reach the legal age of majority to give 
consent for medical procedures in a given country, and (ii) patients have lived continuously for at 
least 12 months in the gender role that is congruent with their gender identity. The age threshold 
should be seen as a minimum criterion and not an indication in and of itself for active intervention. 
Chest surgery in FtM patients could be carried out earlier, preferably after ample time of living in 
the desired gender role and after one year of testosterone treatment. The intent of this suggested 
sequence is to give adolescents sufficient opportunity to experience and socially adjust in a more 
masculine gender role, before undergoing irreversible surgery. However, different approaches may 
be more suitable, depending on an adolescent’s specific clinical situation and goals for gender 
identity expression.
Risks of Withholding Medical Treatment for Adolescents 
Refusing timely medical interventions for adolescents might prolong gender dysphoria and contribute 
to an appearance that could provoke abuse and stigmatization. As the level of gender-related abuse 
is strongly associated with the degree of psychiatric distress during adolescence (Nuttbrock et al., 
2010), withholding puberty suppression and subsequent feminizing or masculinizing hormone 
therapy is not a neutral option for adolescents. 
VII  
Mental Health 
Transsexual, transgender, and gender nonconforming people might seek the assistance of a mental 
health professional for any number of reasons. Regardless of a person’s reason for seeking care, 
mental health professionals should have familiarity with gender nonconformity, act with appropriate 
cultural competence, and exhibit sensitivity in providing care. 
This section of the SOC focuses on the role of mental health professionals in the care of adults 
seeking help for gender dysphoria and related concerns. Professionals working with gender 
dysphoric children, adolescents, and their families should consult section VI.
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Competency of Mental Health Professionals Working 
with Adults Who Present with Gender Dysphoria
The training of mental health professionals competent to work with gender dysphoric adults 
rests upon basic general clinical competence in the assessment, diagnosis, and treatment of 
mental health concerns. Clinical training may occur within any discipline that prepares mental 
health professionals for clinical practice, such as psychology, psychiatry, social work, mental 
health counseling, marriage and family therapy, nursing, or family medicine with specific training 
in behavioral health and counseling. The following are recommended minimum credentials for 
mental health professionals who work with adults presenting with gender dysphoria:
1. A master’s degree or its equivalent in a clinical behavioral science field. This degree, or a more 
advanced one, should be granted by an institution accredited by the appropriate national or re-
gional accrediting board. The mental health professional should have documented credentials 
from a relevant licensing board or equivalent for that country. 
2. Competence in using the Diagnostic Statistical Manual of Mental Disorders and/or the Interna-
tional Classification of Diseases for diagnostic purposes. 
3. Ability to recognize and diagnose co-existing mental health concerns and to distinguish these 
from gender dysphoria.
4. Documented supervised training and competence in psychotherapy or counseling.
5. Knowledgeable about gender nonconforming identities and expressions, and the assessment 
and treatment of gender dysphoria.
6. Continuing education in the assessment and treatment of gender dysphoria. This may include 
attending relevant professional meetings, workshops, or seminars; obtaining supervision from 
a mental health professional with relevant experience; or participating in research related to 
gender nonconformity and gender dysphoria.
In addition to the minimum credentials above, it is recommended that mental health professionals 
develop and maintain cultural competence to facilitate their work with transsexual, transgender, 
and gender nonconforming clients. This may involve, for example, becoming knowledgeable about 
current community, advocacy, and public policy issues relevant to these clients and their families. 
Additionally, knowledge about sexuality, sexual health concerns, and the assessment and treatment 
of sexual disorders is preferred. 
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Mental health professionals who are new to the field (irrespective of their level of training and other 
experience) should work under the supervision of a mental health professional with established 
competence in the assessment and treatment of gender dysphoria.
Tasks of Mental Health Professionals Working with 
Adults Who Present with Gender Dysphoria
Mental health professionals may serve transsexual, transgender, and gender nonconforming 
individuals and their families in many ways, depending on a client’s needs. For example, mental 
health professionals may serve as a psychotherapist, counselor, or family therapist, or as a 
diagnostician/assessor, advocate, or educator. 
Mental health professionals should determine a client’s reasons for seeking professional 
assistance. For example, a client may be presenting for any combination of the following health care 
services: psychotherapeutic assistance to explore gender identity and expression or to facilitate a 
coming out process; assessment and referral for feminizing/masculinizing medical interventions; 
psychological support for family members (partners, children, extended family); psychotherapy 
unrelated to gender concerns; or other professional services.
Below are general guidelines for common tasks that mental health professionals may fulfill in 
working with adults who present with gender dysphoria.
Tasks Related to Assessment and Referral  
1.  Assess gender dysphoria
Mental health professionals assess clients’ gender dysphoria in the context of an evaluation of 
their psychosocial adjustment (Bockting et al., 2006; Lev, 2004, 2009). The evaluation includes, 
at a minimum, assessment of gender identity and gender dysphoria, history and development of 
gender dysphoric feelings, the impact of stigma attached to gender nonconformity on mental health, 
and the availability of support from family, friends, and peers (for example, in-person or online 
contact with other transsexual, transgender, or gender nonconforming individuals or groups). The 
evaluation may result in no diagnosis, in a formal diagnosis related to gender dysphoria, and/or in 
other diagnoses that describe aspects of the client’s health and psychosocial adjustment. The role 
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of mental health professionals includes making reasonably sure that the gender dysphoria is not 
secondary to, or better accounted for, by other diagnoses. 
Mental health professionals with the competencies described above (hereafter called “a qualified 
mental health professional”) are best prepared to conduct this assessment of gender dysphoria. 
However, this task may instead be conducted by another type of health professional who has 
appropriate training in behavioral health and is competent in the assessment of gender dysphoria, 
particularly when functioning as part of a multidisciplinary specialty team that provides access to 
feminizing/masculinizing hormone therapy. This professional may be the prescribing hormone 
therapy provider or a member of that provider’s health care team.
2.  Provide information regarding options for gender identity and expression and possible 
medical interventions
An important task of mental health professionals is to educate clients regarding the diversity of 
gender identities and expressions and the various options available to alleviate gender dysphoria. 
Mental health professionals then may facilitate a process (or refer elsewhere) in which clients 
explore these various options, with the goals of finding a comfortable gender role and expression 
and becoming prepared to make a fully-informed decision about available medical interventions, 
if needed. This process may include referral for individual, family, and group therapy and/or to 
community resources and avenues for peer support. The professional and the client discuss 
the implications, both short- and long-term, of any changes in gender role and use of medical 
interventions. These implications can be psychological, social, physical, sexual, occupational, 
financial, and legal (Bockting et al., 2006; Lev, 2004). 
This task is also best conducted by a qualified mental health professional, but may be conducted 
by another health professional with appropriate training in behavioral health and with sufficient 
knowledge about gender nonconforming identities and expressions and about possible medical 
interventions for gender dysphoria, particularly when functioning as part of a multidisciplinary 
specialty team that provides access to feminizing/masculinizing hormone therapy. 
3.  Assess, diagnose, and discuss treatment options for co-existing mental health concerns 
Clients presenting with gender dysphoria may struggle with a range of mental health concerns 
(Gómez-Gil, Trilla, Salamero, Godás, & Valdés, 2009; Murad et al., 2010) whether related or 
unrelated to what is often a long history of gender dysphoria and/or chronic minority stress. Possible 
concerns include anxiety, depression, self-harm, a history of abuse and neglect, compulsivity, 
substance abuse, sexual concerns, personality disorders, eating disorders, psychotic disorders, and 
autistic spectrum disorders (Bockting et al., 2006; Nuttbrock et al., 2010; Robinow, 2009). Mental 
health professionals should screen for these and other mental health concerns and incorporate 
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the identified concerns into the overall treatment plan. These concerns can be significant sources 
of distress and, if left untreated, can complicate the process of gender identity exploration and 
resolution of gender dysphoria (Bockting et al., 2006; Fraser, 2009a; Lev, 2009). Addressing these 
concerns can greatly facilitate the resolution of gender dysphoria, possible changes in gender role, 
the making of informed decisions about medical interventions, and improvements in quality of life.
Some clients may benefit from psychotropic medications to alleviate symptoms or treat co-
existing mental health concerns. Mental health professionals are expected to recognize this and 
either provide pharmacotherapy or refer to a colleague who is qualified to do so. The presence 
of co-existing mental health concerns does not necessarily preclude possible changes in gender 
role or access to feminizing/masculinizing hormones or surgery; rather, these concerns need to 
be optimally managed prior to, or concurrent with, treatment of gender dysphoria. In addition, 
clients should be assessed for their ability to provide educated and informed consent for medical 
treatments.
Qualified mental health professionals are specifically trained to assess, diagnose, and treat (or 
refer to treatment for) these co-existing mental health concerns. Other health professionals with 
appropriate training in behavioral health, particularly when functioning as part of a multidisciplinary 
specialty team providing access to feminizing/masculinizing hormone therapy, may also screen 
for mental health concerns and, if indicated, provide referral for comprehensive assessment and 
treatment by a qualified mental health professional.
4.  If applicable, assess eligibility, prepare, and refer for hormone therapy
The SOC provide criteria to guide decisions regarding feminizing/masculinizing hormone therapy 
(outlined in section VIII and Appendix C). Mental health professionals can help clients who are 
considering hormone therapy to be both psychologically prepared (e.g., has made a fully informed 
decision with clear and realistic expectations; is ready to receive the service in line with the overall 
treatment plan; has included family and community as appropriate) and practically prepared (e.g., 
has been evaluated by a physician to rule out or address medical contraindications to hormone 
use; has considered the psychosocial implications). If clients are of childbearing age, reproductive 
options (section IX) should be explored before initiating hormone therapy.
It is important for mental health professionals to recognize that decisions about hormones are 
first and foremost a client’s decisions – as are all decisions regarding healthcare. However, mental 
health professionals have a responsibility to encourage, guide, and assist clients with making fully 
informed decisions and becoming adequately prepared. To best support their clients’ decisions, 
mental health professionals need to have functioning working relationships with their clients and 
sufficient information about them. Clients should receive prompt and attentive evaluation, with the 
goal of alleviating their gender dysphoria and providing them with appropriate medical services.  
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Referral for feminizing/masculinizing hormone therapy
People may approach a specialized provider in any discipline to pursue feminizing/masculinizing 
hormone therapy. However, transgender health care is an interdisciplinary field, and coordination 
of care and referral among a client’s overall care team is recommended. 
Hormone therapy can be initiated with a referral from a qualified mental health professional. 
Alternatively, a health professional who is appropriately trained in behavioral health and competent 
in the assessment of gender dysphoria may assess eligibility, prepare, and refer the patient for 
hormone therapy, particularly in the absence of significant co-existing mental health concerns and 
when working in the context of a multidisciplinary specialty team. The referring health professional 
should provide documentation – in the chart and/or referral letter – of the patient’s personal and 
treatment history, progress, and eligibility. Health professionals who recommend hormone therapy 
share the ethical and legal responsibility for that decision with the physician who provides the 
service. 
The recommended content of the referral letter for feminizing/masculinizing hormone therapy is 
as follows: 
1. The client’s general identifying characteristics;
2. Results of the client’s psychosocial assessment, including any diagnoses;
3. The duration of the referring health professional’s relationship with the client, including the 
type of evaluation and therapy or counseling to date; 
4. An explanation that the criteria for hormone therapy have been met, and a brief description of 
the clinical rationale for supporting the client’s request for hormone therapy;
5. A statement about the fact that informed consent has been obtained from the patient;
6. A statement that the referring health professional is available for coordination of care and wel-
comes a phone call to establish this.
For providers working within a multidisciplinary specialty team, a letter may not be necessary; 
rather, the assessment and recommendation can be documented in the patient’s chart.
5.  If applicable, assess eligibility, prepare, and refer for surgery
The SOC also provide criteria to guide decisions regarding breast/chest surgery and genital surgery 
(outlined in section XI and Appendix C). Mental health professionals can help clients who are 
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considering surgery to be both psychologically prepared (e.g., has made a fully informed decision 
with clear and realistic expectations; is ready to receive the service in line with the overall treatment 
plan; has included family and community as appropriate) and practically prepared (for example, 
has made an informed choice about a surgeon to perform the procedure; has arranged aftercare). 
If clients are of childbearing age, reproductive options (section IX) should be explored before 
undergoing genital surgery. 
The SOC do not state criteria for other surgical procedures, such as feminizing or masculinizing 
facial surgery; however, mental health professionals can play an important role in helping their 
clients to make fully informed decisions about the timing and implications of such procedures in 
the context of the overall coming out or transition process.
It is important for mental health professionals to recognize that decisions about surgery are first 
and foremost a client’s decisions – as are all decisions regarding healthcare. However, mental 
health professionals have a responsibility to encourage, guide, and assist clients with making fully 
informed decisions and becoming adequately prepared. To best support their clients’ decisions, 
mental health professionals need to have functioning working relationships with their clients and 
sufficient information about them. Clients should receive prompt and attentive evaluation, with the 
goal of alleviating their gender dysphoria and providing them with appropriate medical services.  
Referral for surgery
Surgical treatments for gender dysphoria can be initiated by a referral (one or two, depending on 
the type of surgery) from a qualified mental health professional. The mental health professional 
provides documentation – in the chart and/or referral letter – of the patient’s personal and 
treatment history, progress, and eligibility. Mental health professionals who recommend surgery 
share the ethical and legal responsibility for that decision with the surgeon.
•	One referral from a qualified mental health professional is needed for breast/chest surgery 
(e.g., mastectomy, chest reconstruction, or augmentation mammoplasty).
•	Two referrals – from qualified mental health professionals who have independently assessed 
the patient – are needed for genital surgery (i.e., hysterectomy/salpingo-oophorectomy, orchi-
ectomy, genital reconstructive surgeries). If the first referral is from the patient’s psychothera-
pist, the second referral should be from a person who has only had an evaluative role with the 
patient. Two separate letters, or one letter signed by both (e.g., if practicing within the same 
clinic) may be sent. Each referral letter, however, is expected to cover the same topics in the 
areas outlined below.
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The recommended content of the referral letters for surgery is as follows: 
1. The client’s general identifying characteristics;
2. Results of the client’s psychosocial assessment, including any diagnoses;
3. The duration of the mental health professional’s relationship with the client, including the type 
of evaluation and therapy or counseling to date; 
4. An explanation that the criteria for surgery have been met, and a brief description of the clinical 
rationale for supporting the patient’s request for surgery;
5. A statement about the fact that informed consent has been obtained from the patient;
6. A statement that the mental health professional is available for coordination of care and wel-
comes a phone call to establish this.
For providers working within a multidisciplinary specialty team, a letter may not be necessary, 
rather, the assessment and recommendation can be documented in the patient’s chart.
Relationship of Mental Health Professionals with Hormone-
Prescribing Physicians, Surgeons, and other Health Professionals
It is ideal for mental health professionals to perform their work and periodically discuss progress 
and obtain peer consultation from other professionals (both in mental health care and other 
health disciplines) who are competent in the assessment and treatment of gender dysphoria. The 
relationship among professionals involved in a client’s health care should remain collaborative, with 
coordination and clinical dialogue taking place as needed. Open and consistent communication 
may be necessary for consultation, referral, and management of postoperative concerns.
Tasks Related to Psychotherapy 
1.  Psychotherapy is not an absolute requirement for hormone therapy and surgery
A mental health screening and/or assessment as outlined above is needed for referral to hormonal 
and surgical treatments for gender dysphoria. In contrast, psychotherapy – although highly 
recommended – is not a requirement. 
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The SOC do not recommend a minimum number of psychotherapy sessions prior to hormone 
therapy or surgery. The reasons for this are multifaceted (Lev, 2009). First, a minimum number of 
sessions tends to be construed as a hurdle, which discourages the genuine opportunity for personal 
growth. Second, mental health professionals can offer important support to clients throughout all 
phases of exploration of gender identity, gender expression, and possible transition – not just 
prior to any possible medical interventions. Third, clients and their psychotherapists differ in their 
abilities to attain similar goals in a specified time period.
2.  Goals of psychotherapy for adults with gender concerns 
The general goal of psychotherapy is to find ways to maximize a person’s overall psychological well-
being, quality of life, and self-fulfillment. Psychotherapy is not intended to alter a person’s gender 
identity; rather, psychotherapy can help an individual to explore gender concerns and find ways 
to alleviate gender dysphoria, if present (Bockting et al., 2006; Bockting & Coleman, 2007; Fraser, 
2009a; Lev, 2004). Typically, the overarching treatment goal is to help transsexual, transgender, and 
gender nonconforming individuals achieve long-term comfort in their gender identity expression, 
with realistic chances for success in their relationships, education, and work. For additional details, 
see Fraser (Fraser, 2009c). 
Therapy may consist of individual, couple, family, or group psychotherapy, the latter being 
particularly important to foster peer support. 
3.  Psychotherapy for transsexual, transgender, and gender nonconforming clients, including 
counseling and support for changes in gender role
Finding a comfortable gender role is, first and foremost, a psychosocial process. Psychotherapy 
can be invaluable in assisting transsexual, transgender, and gender nonconforming individuals 
with all of the following: (i) clarifying and exploring gender identity and role, (ii) addressing the 
impact of stigma and minority stress on one’s mental health and human development, and 
(iii) facilitating a coming out process (Bockting & Coleman, 2007; Devor, 2004; Lev, 2004), which 
for some individuals may include changes in gender role expression and the use of feminizing/
masculinizing medical interventions. 
Mental health professionals can provide support and promote interpersonal skills and resilience 
in individuals and their families as they navigate a world that often is ill-prepared to accommodate 
and respect transgender, transsexual, and gender nonconforming people. Psychotherapy can also 
aid in alleviating any co-existing mental health concerns (e.g., anxiety, depression) identified during 
screening and assessment. 
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For transsexual, transgender, and gender nonconforming individuals who plan to change gender 
roles permanently and make a social gender role transition, mental health professionals can 
facilitate the development of an individualized plan with specific goals and timelines. While the 
experience of changing one’s gender role differs from person to person, the social aspects of the 
experience are usually challenging – often more so than the physical aspects. Because changing 
gender role can have profound personal and social consequences, the decision to do so should 
include an awareness of what the familial, interpersonal, educational, vocational, economic, and 
legal challenges are likely to be, so that people can function successfully in their gender role. 
Many transsexual, transgender, and gender nonconforming people will present for care without 
ever having been related to, or accepted in, the gender role that is most congruent with their 
gender identity. Mental health professionals can help these clients to explore and anticipate the 
implications of changes in gender role, and to pace the process of implementing these changes. 
Psychotherapy can provide a space for clients to begin to express themselves in ways that are 
congruent with their gender identity and, for some clients, overcome fears about changes in gender 
expression. Calculated risks can be taken outside of therapy to gain experience and build confidence 
in the new role. Assistance with coming out to family and community (friends, school, workplace) 
can be provided. 
Other transsexual, transgender, and gender nonconforming individuals will present for care already 
having acquired experience (minimal, moderate, or extensive) living in a gender role that differs 
from that associated with their birth-assigned sex. Mental health professionals can help these 
clients to identify and work through potential challenges and foster optimal adjustment as they 
continue to express changes in their gender role.
4.  Family therapy or support for family members
Decisions about changes in gender role and medical interventions for gender dysphoria have 
implications for not only clients, but also their families (Emerson & Rosenfeld, 1996; Fraser, 
2009a; Lev, 2004). Mental health professionals can assist clients with making thoughtful decisions 
about communicating with family members and others about their gender identity and treatment 
decisions. Family therapy may include work with spouses or partners, as well as with children and 
other members of a client’s extended family.
Clients may also request assistance with their relationships and sexual health. For example, they 
may want to explore their sexuality and intimacy related concerns. 
Family therapy might be offered as part of the client’s individual therapy and, if clinically appropriate, 
by the same provider. Alternatively, referrals can be made to other therapists with relevant expertise 
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to work with family members, or to sources of peer support (e.g.,  in person or offline support 
networks of partners or families).
5.  Follow-up care throughout life
Mental health professionals may work with clients and their families at many stages of their lives. 
Psychotherapy may be helpful at different times and for various issues throughout the life cycle.
6.  Etherapy, online counseling, or distance counseling 
Online or etherapy has been shown to be particularly useful for people who have difficulty 
accessing competent in person psychotherapeutic treatment and who may experience isolation 
and stigma (Derrig-Palumbo & Zeine, 2005; Fenichel et al., 2004; Fraser, 2009b). By extrapolation, 
etherapy may be a useful modality for psychotherapy with transsexual, transgender, and gender 
nonconforming people. Etherapy offers opportunities for potentially enhanced, expanded, creative, 
and tailored delivery of services; however, as a developing modality it may also carry unexpected 
risk. Telemedicine guidelines are clear in some disciplines in some parts of the United States 
(Fraser, 2009b; Maheu, Pulier, Wilhelm, McMenamin, & Brown-Connolly, 2005) but not all; the 
international situation is even less well-defined (Maheu et al., 2005). Until sufficient evidence-
based data on this use of etherapy is available, caution in its use is advised.
Mental health professionals engaging in etherapy are advised to stay current with their particular 
licensing board, professional association, and country’s regulations, as well as the most recent 
literature pertaining to this rapidly evolving medium. A more thorough description of the potential 
uses, processes, and ethical concerns related to etherapy has been published (Fraser, 2009b).
Other Tasks of Mental Health Professionals
1.  Educate and advocate on behalf of clients within their community (schools, workplaces, 
other organizations) and assist clients with making changes in identity documents 
Transsexual, transgender, and gender nonconforming people may face challenges in their 
professional, educational, and other types of settings as they actualize their gender identity and 
expression (Lev, 2004, 2009). Mental health professionals can play an important role by educating 
people in these settings regarding gender nonconformity and by advocating on behalf of their 
clients (Currah, Juang, & Minter, 2006; Currah & Minter, 2000). This role may involve consultation 
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with school counselors, teachers, and administrators, human resources staff, personnel managers 
and employers, and representatives from other organizations and institutions. In addition, health 
providers may be called upon to support changes in a client’s name and/or gender marker on 
identity documents such as passports, driver’s licenses, birth certificates, and diplomas.  
2.  Provide information and referral for peer support 
For some transsexual, transgender, and gender nonconforming people, an experience in peer 
support groups may be more instructive regarding options for gender expression than anything 
individual psychotherapy could offer (Rachlin, 2002). Both experiences are potentially valuable, and 
all people exploring gender issues should be encouraged to participate in community activities, if 
possible. Resources for peer support and information should be made available.
Culture and its Ramifications for Assessment and Psychotherapy
Health professionals work in enormously different environments across the world. Forms of 
distress that cause people to seek professional assistance in any culture are understood and 
classified by people in terms that are products of their own cultures (Frank & Frank, 1993). Cultural 
settings also largely determine how such conditions are understood by mental health professionals. 
Cultural differences related to gender identity and expression can affect patients, mental health 
professionals, and accepted psychotherapy practice. WPATH recognizes that the SOC have grown 
out of a Western tradition and may need to be adapted depending on the cultural context.
Ethical Guidelines Related to Mental Health Care
Mental health professionals need to be certified or licensed to practice in a given country according 
to that country’s professional regulations (Fraser, 2009b; Pope & Vasquez, 2011). Professionals 
must adhere to the ethical codes of their professional licensing or certifying organizations in all of 
their work with transsexual, transgender, and gender nonconforming clients.
Treatment aimed at trying to change a person’s gender identity and lived gender expression to 
become more congruent with sex assigned at birth has been attempted in the past (Gelder & 
Marks, 1969; Greenson, 1964), yet without success, particularly in the long term (Cohen-Kettenis 
& Kuiper, 1984; Pauly, 1965). Such treatment is no longer considered ethical. 
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If mental health professionals are uncomfortable with, or inexperienced in, working with transsexual, 
transgender, and gender nonconforming individuals and their families, they should refer clients 
to a competent provider or, at minimum, consult with an expert peer. If no local practitioners 
are available, consultation may be done via telehealth methods, assuming local requirements for 
distance consultation are met. 
Issues of Access to Care
Qualified mental health professionals are not universally available; thus, access to quality care 
might be limited. WPATH aims to improve access and provides regular continuing education 
opportunities to train professionals from various disciplines to provide quality, transgender-specific 
health care. Providing mental health care from a distance through the use of technology may be 
one way to improve access (Fraser, 2009b).
In many places around the world, access to health care for transsexual, transgender, and gender 
nonconforming people is also limited by a lack of health insurance or other means to pay for needed 
care. WPATH urges health insurance companies and other third-party payers to cover the medically 
necessary treatments to alleviate gender dysphoria (American Medical Association, 2008; Anton, 
2009; The World Professional Association for Transgender Health, 2008). 
When faced with a client who is unable to access services, referral to available peer support 
resources (offline and online) is recommended. Finally, harm reduction approaches might be 
indicated to assist clients with making healthy decisions to improve their lives. 
VIII  
Hormone Therapy 
Medical Necessity of Hormone Therapy
Feminizing/masculinizing hormone therapy – the administration of exogenous endocrine agents 
to induce feminizing or masculinizing changes – is a medically necessary intervention for many 
transsexual, transgender, and gender nonconforming individuals with gender dysphoria (Newfield, 
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Hart, Dibble, & Kohler, 2006; Pfäfflin & Junge, 1998). Some people seek maximum feminization/ 
masculinization, while others experience relief with an androgynous presentation resulting from 
hormonal minimization of existing secondary sex characteristics (Factor & Rothblum, 2008). 
Evidence for the psychosocial outcomes of hormone therapy is summarized in Appendix D.
Hormone therapy must be individualized based on a patient’s goals, the risk/benefit ratio of 
medications, the presence of other medical conditions, and consideration of social and economic 
issues. Hormone therapy can provide significant comfort to patients who do not wish to make 
a social gender role transition or undergo surgery, or who are unable to do so (Meyer III, 2009). 
Hormone therapy is a recommended criterion for some, but not all, surgical treatments for gender 
dysphoria (see section XI and Appendix C). 
Criteria for Hormone Therapy 
Initiation of hormone therapy may be undertaken after a psychosocial assessment has been 
conducted and informed consent has been obtained by a qualified health professional, as outlined 
in section VII of the SOC. A referral is required from the mental health professional who performed 
the assessment, unless the assessment was done by a hormone provider who is also qualified in 
this area.
The criteria for hormone therapy are as follows: 
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC outlined in section VI);
4. If significant medical or mental health concerns are present, they must be reasonably well-
controlled.
As noted in section VII of the SOC, the presence of co-existing mental health concerns does not 
necessarily preclude access to feminizing/masculinizing hormones; rather, these concerns need to 
be managed prior to, or concurrent with, treatment of gender dysphoria.
In selected circumstances, it can be acceptable practice to provide hormones to patients who have 
not fulfilled these criteria. Examples include facilitating the provision of monitored therapy using 
hormones of known quality as an alternative to illicit or unsupervised hormone use or to patients 
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who have already established themselves in their affirmed gender and who have a history of prior 
hormone use. It is unethical to deny availability or eligibility for hormone therapy solely on the basis 
of blood seropositivity for blood-borne infections such as HIV or hepatitis B or C.
In rare cases, hormone therapy may be contraindicated due to serious individual health conditions. 
Health professionals should assist these patients with accessing non-hormonal interventions for 
gender dysphoria. A qualified mental health professional familiar with the patient is an excellent 
resource in these circumstances.
Informed Consent
Feminizing/masculinizing hormone therapy may lead to irreversible physical changes. Thus, 
hormone therapy should be provided only to those who are legally able to provide informed 
consent. This includes people who have been declared by a court to be emancipated minors, 
incarcerated people, and cognitively impaired people who are considered competent to participate 
in their medical decisions (Bockting et al., 2006). Providers should document in the medical record 
that comprehensive information has been provided and understood about all relevant aspects of 
the hormone therapy, including both possible benefits and risks and the impact on reproductive 
capacity.
Relationship between the Standards of Care 
and Informed Consent Model Protocols
A number of community health centers in the United States have developed protocols for providing 
hormone therapy based on an approach that has become known as the Informed Consent Model 
(Callen Lorde Community Health Center, 2000, 2011; Fenway Community Health Transgender 
Health Program, 2007; Tom Waddell Health Center, 2006). These protocols are consistent with 
the guidelines presented in the WPATH Standards of Care, Version 7. The SOC are flexible clinical 
guidelines; they allow for tailoring of interventions to the needs of the individual receiving services 
and for tailoring of protocols to the approach and setting in which these services are provided 
(Ehrbar & Gorton, 2010). 
Obtaining informed consent for hormone therapy is an important task of providers to ensure 
that patients understand the psychological and physical benefits and risks of hormone therapy, as 
well as its psychosocial implications. Providers prescribing the hormones or health professionals 
recommending the hormones should have the knowledge and experience to assess gender 
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dysphoria. They should inform individuals of the particular benefits, limitations, and risks of 
hormones, given the patient’s age, previous experience with hormones, and concurrent physical or 
mental health concerns. 
Screening for and addressing acute or current mental health concerns is an important part of the 
informed consent process. This may be done by a mental health professional or by an appropriately 
trained prescribing provider (see section VII of the SOC). The same provider or another appropriately 
trained member of the health care team (e.g., a nurse) can address the psychosocial implications 
of taking hormones when necessary (e.g., the impact of masculinization/feminization on how 
one is perceived and its potential impact on relationships with family, friends, and coworkers). 
If indicated, these providers will make referrals for psychotherapy and for the assessment and 
treatment of co-existing mental health concerns such as anxiety or depression. 
The difference between the Informed Consent Model and SOC, Version 7 is that the SOC puts 
greater emphasis on the important role that mental health professionals can play in alleviating 
gender dysphoria and facilitating changes in gender role and psychosocial adjustment. This may 
include a comprehensive mental health assessment and psychotherapy, when indicated. In the 
Informed Consent Model, the focus is on obtaining informed consent as the threshold for the 
initiation of hormone therapy in a multidisciplinary, harm-reduction environment. Less emphasis is 
placed on the provision of mental health care until the patient requests it, unless significant mental 
health concerns are identified that would need to be addressed before hormone prescription.
Physical Effects of Hormone Therapy
Feminizing/masculinizing hormone therapy will induce physical changes that are more congruent 
with a patient’s gender identity.
•	In FtM patients, the following physical changes are expected to occur: deepened voice, cli-
toral enlargement (variable), growth in facial and body hair, cessation of menses, atrophy of 
breast tissue, and decreased percentage of body fat compared to muscle mass.
•	In MtF patients, the following physical changes are expected to occur: breast growth (vari-
able), decreased erectile function, decreased testicular size, and increased percentage of body 
fat compared to muscle mass.
Most physical changes, whether feminizing or masculinizing, occur over the course of two years. 
The amount of physical change and the exact timeline of effects can be highly variable. Tables 1a 
and 1b outline the approximate time course of these physical changes.
37
The Standards of Care 
7TH VERSION
World Professional Association for Transgender Health
TABLE 1A:  EFFECTS AND EXPECTED TIME COURSE OF MASCULINIZING HORMONES a
Effect Expected Onsetb Expected Maximum Effectb
Skin oiliness/acne 1-6 months 1-2 years
Facial/body hair growth 3-6 months 3-5 years
Scalp hair loss >12 monthsc variable
Increased muscle mass/strength 6-12 months 2-5 yearsd
Body fat redistribution 3-6 months 2-5 years
Cessation of menses 2-6 months n/a
Clitoral enlargement 3-6 months 1-2 years
Vaginal atrophy 3-6 months 1-2 years
Deepened voice 3-12 months 1-2 years
 A Adapted with permission from Hembree et al.(2009). Copyright 2009, The Endocrine Society.
 B Estimates represent published and unpublished clinical observations.
 C Highly dependent on age and inheritance; may be minimal.
 D Significantly dependent on amount of exercise.
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TABLE 1B:  EFFECTS AND EXPECTED TIME COURSE OF FEMINIZING HORMONES a
Effect Expected Onsetb Expected Maximum Effectb
Body fat redistribution 3-6 months 2-5 years
Decreased muscle mass/
strength
3-6 months 1-2 yearsc
Softening of skin/decreased 
oiliness
3-6 months unknown
Decreased libido 1-3 months 1-2 years
Decreased spontaneous 
erections
1-3 months 3-6 months
Male sexual dysfunction variable variable
Breast growth 3-6 months 2-3 years
Decreased testicular volume 3-6 months 2-3 years
Decreased sperm production variable variable
Thinning and slowed growth of 
body and facial hair
6-12 months > 3 yearsd
Male pattern baldness
No regrowth, loss 
stops 1-3 months
1-2 years
 a Adapted with permission from Hembree et al. (2009). Copyright 2009, The Endocrine Society.
 b Estimates represent published and unpublished clinical observations.
 c Significantly dependent on amount of exercise. 
 d Complete removal of male facial and body hair requires electrolysis, laser treatment, or both. 
The degree and rate of physical effects depends in part on the dose, route of administration, 
and medications used, which are selected in accordance with a patient’s specific medical goals 
(e.g.,  changes in gender role expression, plans for sex reassignment) and medical risk profile. 
There is no current evidence that response to hormone therapy – with the possible exception of 
voice deepening in FtM persons – can be reliably predicted based on age, body habitus, ethnicity, or 
family appearance. All other factors being equal, there is no evidence to suggest that any medically 
approved type or method of administering hormones is more effective than any other in producing 
the desired physical changes. 
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Risks of Hormone Therapy
All medical interventions carry risks. The likelihood of a serious adverse event is dependent on 
numerous factors: the medication itself, dose, route of administration, and a patient’s clinical 
characteristics (age, co-morbidities, family history, health habits). It is thus impossible to predict 
whether a given adverse effect will happen in an individual patient. 
The risks associated with feminizing/masculinizing hormone therapy for the transsexual, 
transgender, and gender nonconforming population as a whole are summarized in Table 2. Based 
on the level of evidence, risks are categorized as follows: (i)  likely increased risk with hormone 
therapy, (ii) possibly increased risk with hormone therapy, or (iii) inconclusive or no increased risk. 
Items in the last category include those that may present risk, but for which the evidence is so 
minimal that no clear conclusion can be reached. 
Additional detail about these risks can be found in Appendix B, which is based on two comprehensive, 
evidence-based literature reviews of masculinizing/feminizing hormone therapy (Feldman & Safer, 
2009; Hembree et al., 2009), along with a large cohort study (Asscheman et al., 2011). These 
reviews can serve as detailed references for providers, along with other widely recognized, published 
clinical materials (Dahl, Feldman, Goldberg, & Jaberi, 2006; Ettner, Monstrey, & Eyler, 2007). 
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TABLE 2:  RISKS ASSOCIATED WITH HORMONE THERAPY. BOLDED ITEMS ARE CLINICALLY SIGNIFICANT














Likely increased risk with  
presence of additional risk 
factorsb
Cardiovascular disease






Possible increased risk  with 
presence of additional risk 
factorsB
Type 2 diabetesa





No increased risk or 
inconclusive Breast cancer





 a Risk is greater with oral estrogen administration than with transdermal estrogen administration.
 b Additional risk factors include age.
 c Includes bipolar, schizoaffective, and other disorders that may include manic or psychotic symptoms. This adverse event 
appears to be associated with higher doses or supraphysiologic blood levels of testosterone.
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Competency of Hormone-Prescribing Physicians, 
Relationship with Other Health Professionals
Feminizing/masculinizing hormone therapy is best undertaken in the context of a complete 
approach to health care that includes comprehensive primary care and a coordinated approach to 
psychosocial issues (Feldman & Safer, 2009). While psychotherapy or ongoing counseling is not 
required for the initiation of hormone therapy, if a therapist is involved, then regular communication 
among health professionals is advised (with the patient’s consent) to ensure that the transition 
process is going well, both physically and psychosocially.
With appropriate training, feminizing/masculinizing hormone therapy can be managed by a variety 
of providers, including nurse practitioners, physician assistants, and primary care physicians (Dahl 
et al., 2006). Medical visits relating to hormone maintenance provide an opportunity to deliver 
broader care to a population that is often medically underserved (Clements, Wilkinson, Kitano, 
& Marx, 1999; Feldman, 2007; Xavier, 2000). Many of the screening tasks and management of 
co-morbidities associated with long-term hormone use, such as cardiovascular risk factors and 
cancer screening, fall more uniformly within the scope of primary care rather than specialist care 
(American Academy of Family Physicians, 2005; Eyler, 2007; World Health Organization, 2008), 
particularly in locations where dedicated gender teams or specialized physicians are not available.
Given the multidisciplinary needs of transsexual, transgender, and gender nonconforming people 
seeking hormone therapy, as well as the difficulties associated with fragmentation of care in general 
(World Health Organization, 2008), WPATH strongly encourages the increased training and 
involvement of primary care providers in the area of feminizing/masculinizing hormone therapy. If 
hormones are prescribed by a specialist, there should be close communication with the patient’s 
primary care provider. Conversely, an experienced hormone provider or endocrinologist should be 
involved if the primary care physician has no experience with this type of hormone therapy, or if 
the patient has a pre-existing metabolic or endocrine disorder that could be affected by endocrine 
therapy.
While formal training programs in transgender medicine do not yet exist, hormone providers 
have a responsibility to obtain appropriate knowledge and experience in this field. Clinicians can 
increase their experience and comfort in providing feminizing/masculinizing hormone therapy by 
co-managing care or consulting with a more experienced provider, or by providing more limited 
types of hormone therapy before progressing to initiation of hormone therapy. Because this field 
of medicine is evolving, clinicians should become familiar and keep current with the medical 
literature, and discuss emerging issues with colleagues. Such discussions might occur through 
networks established by WPATH and other national/local organizations. 
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Responsibilities of Hormone-Prescribing Physicians
In general, clinicians who prescribe hormone therapy should engage in the following tasks:
1. Perform an initial evaluation that includes discussion of a patient’s physical transition goals, 
health history, physical examination, risk assessment, and relevant laboratory tests. 
2. Discuss with patients the expected effects of feminizing/masculinizing medications and the 
possible adverse health effects. These effects can include a reduction in fertility (Feldman & 
Safer, 2009; Hembree et al., 2009). Therefore, reproductive options should be discussed with 
patients before starting hormone therapy (see section IX).
3. Confirm that patients have the capacity to understand the risks and benefits of treatment and 
are capable of making an informed decision about medical care. 
4. Provide ongoing medical monitoring, including regular physical and laboratory examination to 
monitor hormone effectiveness and side effects.
5. Communicate as needed with a patient’s primary care provider, mental health professional, 
and surgeon.
6. If needed, provide patients with a brief written statement indicating that they are under medi-
cal supervision and care that includes feminizing/masculinizing hormone therapy. Particularly 
during the early phases of hormone treatment, a patient may wish to carry this statement at all 
times to help prevent difficulties with the police and other authorities. 
Depending on the clinical situation for providing hormones (see below), some of these 
responsibilities are less relevant. Thus, the degree of counseling, physical examinations, and 
laboratory evaluations should be individualized to a patient’s needs. 
Clinical Situations for Hormone Therapy
There are circumstances in which clinicians may be called upon to provide hormones without 
necessarily initiating or maintaining long-term feminizing/masculinizing hormone therapy. 
By acknowledging these different clinical situations (see below, from least to highest level of 
complexity), it may be possible to involve clinicians in feminizing/masculinizing hormone therapy 
who might not otherwise feel able to offer this treatment. 
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1. Bridging
Whether prescribed by another clinician or obtained through other means (e.g., purchased over 
the internet), patients may present for care already on hormone therapy. Clinicians can provide 
a limited (1-6 month) prescription for hormones while helping patients find a provider who can 
prescribe long-term hormone therapy. Providers should assess a patient’s current regimen for 
safety and drug interactions and substitute safer medications or doses when indicated (Dahl et al., 
2006; Feldman & Safer, 2009). If hormones were previously prescribed, medical records should 
be requested (with the patient’s permission) to obtain the results of baseline examinations and 
laboratory tests and any adverse events. Hormone providers should also communicate with any 
mental health professional who is currently involved in a patient’s care. If a patient has never had 
a psychosocial assessment as recommended by the SOC (see section VII), clinicians should refer 
the patient to a qualified mental health professional if appropriate and feasible (Feldman & Safer, 
2009). Providers who prescribe bridging hormones need to work with patients to establish limits 
as to the duration of bridging therapy. 
2. Hormone therapy following gonad removal
Hormone replacement with estrogen or testosterone is usually continued lifelong after an 
oophorectomy or orchiectomy, unless medical contraindications arise. Because hormone doses 
are often decreased after these surgeries (Basson, 2001; Levy, Crown, & Reid, 2003; Moore, 
Wisniewski, & Dobs, 2003) and only adjusted for age and co-morbid health concerns, hormone 
management in this situation is quite similar to hormone replacement in any hypogonadal patient. 
3. Hormone maintenance prior to gonad removal 
Once patients have achieved maximal feminizing/masculinizing benefits from hormones (typically 
two or more years), they remain on a maintenance dose. The maintenance dose is then adjusted 
for changes in health conditions, aging, or other considerations such as lifestyle changes (Dahl et 
al., 2006). When a patient on maintenance hormones presents for care, the provider should assess 
the patient’s current regimen for safety and drug interactions and substitute safer medications or 
doses when indicated. The patient should continue to be monitored by physical examinations and 
laboratory testing on a regular basis, as outlined in the literature (Feldman & Safer, 2009; Hembree 
et al., 2009). The dose and form of hormones should be revisited regularly with any changes in the 
patient’s health status and available evidence on the potential long-term risks of hormones (See 
Hormone Regimens, below). 
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4. Initiating hormonal feminization/masculinization 
This clinical situation requires the greatest commitment in terms of provider time and expertise. 
Hormone therapy must be individualized based on a patient’s goals, the risk/benefit ratio of 
medications, the presence of other medical conditions, and consideration of social and economic 
issues. Although a wide variety of hormone regimens have been published (Dahl et al., 2006; 
Hembree et al., 2009; Moore et al., 2003), there are no published reports of randomized clinical 
trials comparing safety and efficacy. Despite this variation, a reasonable framework for initial risk 
assessment and ongoing monitoring of hormone therapy can be constructed, based on the efficacy 
and safety evidence presented above. 
Risk Assessment and Modification for 
Initiating Hormone Therapy
The initial evaluation for hormone therapy assesses a patient’s clinical goals and risk factors for 
hormone-related adverse events. During the risk assessment, the patient and clinician should 
develop a plan for reducing risks wherever possible, either prior to initiating therapy or as part of 
ongoing harm reduction. 
All assessments should include a thorough physical exam, including weight, height, and blood 
pressure. The need for breast, genital, and rectal exams, which are sensitive issues for most 
transsexual, transgender, and gender nonconforming patients, should be based on individual risks 
and preventive health care needs (Feldman & Goldberg, 2006; Feldman, 2007). 
Preventive care
Hormone providers should address preventive health care with patients, particularly if a patient 
does not have a primary care provider. Depending on a patient’s age and risk profile, there may 
be appropriate screening tests or exams for conditions affected by hormone therapy. Ideally, these 
screening tests should be carried out prior to the start of hormone therapy.
Risk assessment and modification for feminizing hormone therapy (MtF)
There are no absolute contraindications to feminizing therapy per se, but absolute contraindications 
exist for the different feminizing agents, particularly estrogen. These include previous venous 
thrombotic events related to an underlying hypercoagulable condition, history of estrogen-sensitive 
neoplasm, and end-stage chronic liver disease (Gharib et al., 2005). 
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Other medical conditions, as noted in Table 2 and Appendix B, can be exacerbated by estrogen 
or androgen blockade, and therefore should be evaluated and reasonably well controlled prior 
to starting hormone therapy (Feldman & Safer, 2009; Hembree et al., 2009). Clinicians should 
particularly attend to tobacco use, as it is associated with increased risk of venous thrombosis, 
which is further increased with estrogen use. Consultation with a cardiologist may be advisable for 
patients with known cardio- or cerebrovascular disease. 
Baseline laboratory values are important to both assess initial risk and evaluate possible future 
adverse events. Initial labs should be based on the risks of feminizing hormone therapy outlined 
in Table 2, as well as individual patient risk factors, including family history. Suggested initial lab 
panels have been published (Feldman & Safer, 2009; Hembree et al., 2009). These can be modified 
for patients or health care systems with limited resources, and in otherwise healthy patients.
Risk assessment and modification for masculinizing hormone therapy (FtM)
Absolute contraindications to testosterone therapy include pregnancy, unstable coronary artery 
disease, and untreated polycythemia with a hematocrit of 55% or higher (Carnegie, 2004). Because 
the aromatization of testosterone to estrogen may increase risk in patients with a history of breast 
or other estrogen dependent cancers (Moore et al., 2003), consultation with an oncologist may be 
indicated prior to hormone use. Co-morbid conditions likely to be exacerbated by testosterone use 
should be evaluated and treated, ideally prior to starting hormone therapy (Feldman & Safer, 2009; 
Hembree et al., 2009). Consultation with a cardiologist may be advisable for patients with known 
cardio- or cerebrovascular disease.
An increased prevalence of polycystic ovarian syndrome (PCOS) has been noted among FtM 
patients even in the absence of testosterone use (Baba et al., 2007; Balen, Schachter, Montgomery, 
Reid, & Jacobs, 1993; Bosinski et al., 1997). While there is no evidence that PCOS is related to the 
development of a transsexual, transgender, or gender nonconforming identity, PCOS is associated 
with increased risk of diabetes, cardiac disease, high blood pressure, and ovarian and endometrial 
cancers (Cattrall & Healy, 2004). Signs and symptoms of PCOS should be evaluated prior to 
initiating testosterone therapy, as testosterone may affect many of these conditions. Testosterone 
can affect the developing fetus (Physicians’ Desk Reference, 2010), and patients at risk of becoming 
pregnant require highly effective birth control.
Baseline laboratory values are important to both assess initial risk and evaluate possible future 
adverse events. Initial labs should be based on the risks of masculinizing hormone therapy outlined 
in Table 2, as well as individual patient risk factors, including family history. Suggested initial lab 
panels have been published (Feldman & Safer, 2009; Hembree et al., 2009). These can be modified 
for patients or health care systems with limited resources, and in otherwise healthy patients.
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Clinical Monitoring during Hormone Therapy 
for Efficacy and Adverse Events
The purpose of clinical monitoring during hormone use is to assess the degree of feminization/
masculinization and the possible presence of adverse effects of medication. However, as with 
the monitoring of any long-term medication, monitoring should take place in the context of 
comprehensive health care. Suggested clinical monitoring protocols have been published (Feldman 
& Safer, 2009; Hembree et al., 2009). Patients with co-morbid medical conditions may need to be 
monitored more frequently. Healthy patients in geographically remote or resource-poor areas may 
be able to use alternative strategies, such as telehealth, or cooperation with local providers such 
as nurses and physician assistants. In the absence of other indications, health professionals may 
prioritize monitoring for those risks that are either likely to be increased by hormone therapy or 
possibly increased by hormone therapy but clinically serious in nature. 
Efficacy and risk monitoring during feminizing hormone therapy (MtF)
The best assessment of hormone efficacy is clinical response: Is a patient developing a feminized 
body while minimizing masculine characteristics, consistent with that patient’s gender goals? In 
order to more rapidly predict the hormone dosages that will achieve clinical response, one can 
measure testosterone levels for suppression below the upper limit of the normal female range, 
and estradiol levels within a premenopausal female range but well below supraphysiologic levels 
(Feldman & Safer, 2009; Hembree et al., 2009). 
Monitoring for adverse events should include both clinical and laboratory evaluation. Follow-
up should include careful assessment for signs of cardiovascular impairment and venous 
thromboembolism (VTE) through measurement of blood pressure, weight, and pulse; heart and 
lung exams; and examination of the extremities for peripheral edema, localized swelling, or pain 
(Feldman & Safer, 2009). Laboratory monitoring should be based on the risks of hormone therapy 
described above, a patient’s individual co-morbidities and risk factors, and the specific hormone 
regimen itself. Specific lab monitoring protocols have been published (Feldman & Safer, 2009; 
Hembree et al., 2009). 
Efficacy and risk monitoring during masculinizing hormone therapy (FtM)
The best assessment of hormone efficacy is clinical response: Is a patient developing a masculinized 
body while minimizing feminine characteristics, consistent with that patient’s gender goals? 
Clinicians can achieve a good clinical response with the least likelihood of adverse events by 
maintaining testosterone levels within the normal male range while avoiding supraphysiological 
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levels (Dahl et al., 2006; Hembree et al., 2009). For patients using intramuscular (IM) testosterone 
cypionate or enanthate, some clinicians check trough levels while others prefer midcycle levels 
(Dahl et al., 2006; Hembree et al., 2009; Tangpricha, Turner, Malabanan, & Holick, 2001; Tangpricha, 
Ducharme, Barber, & Chipkin, 2003). 
Monitoring for adverse events should include both clinical and laboratory evaluation. Follow-up 
should include careful assessment for signs and symptoms of excessive weight gain, acne, uterine 
break-through bleeding, and cardiovascular impairment, as well as psychiatric symptoms in at-
risk patients. Physical examinations should include measurement of blood pressure, weight, and 
pulse; and heart, lung, and skin exams (Feldman & Safer, 2009). Laboratory monitoring should be 
based on the risks of hormone therapy described above, a patient’s individual co-morbidities and 
risk factors, and the specific hormone regimen itself. Specific lab monitoring protocols have been 
published (Feldman & Safer, 2009; Hembree et al., 2009). 
Hormone Regimens
To date, no controlled clinical trials of any feminizing/masculinizing hormone regimen have 
been conducted to evaluate safety or efficacy in producing physical transition. As a result, wide 
variation in doses and types of hormones have been published in the medical literature (Moore 
et al., 2003; Tangpricha et al., 2003; van Kesteren, Asscheman, Megens, & Gooren, 1997). In 
addition, access to particular medications may be limited by a patient’s geographical location and/
or social or econonomic situations. For these reasons, WPATH does not describe or endorse a 
particular feminizing/masculinizing hormone regimen. Rather, the medication classes and routes 
of administration used in most published regimens are broadly reviewed.
As outlined above, there are demonstrated safety differences in individual elements of various 
regimens. The Endocrine Society Guidelines (Hembree et al., 2009) and Feldman and Safer (2009) 
provide specific guidance regarding the types of hormones and suggested dosing to maintain 
levels within physiologic ranges for a patient’s desired gender expression (based on goals of full 
feminization/masculinization). It is strongly recommend that hormone providers regularly review 
the literature for new information and use those medications that safely meet individual patient 
needs with available local resources.
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Regimens for feminizing hormone therapy (MtF)
Estrogen
Use of oral estrogen, and specifically ethinyl estradiol, appears to increase the risk of VTE. Because 
of this safety concern, ethinyl estradiol is not recommended for feminizing hormone therapy. 
Transdermal estrogen is recommended for those patients with risks factors for VTE. The risk of 
adverse events increases with higher doses, particular doses resulting in supraphysiologic levels 
(Hembree et al., 2009). Patients with co-morbid conditions that can be affected by estrogen should 
avoid oral estrogen if possible and be started at lower levels. Some patients may not be able to 
safely use the levels of estrogen needed to get the desired results. This possibility needs to be 
discussed with patients well in advance of starting hormone therapy. 
Androgen reducing medications (“anti-androgens”)
A combination of estrogen and “anti-androgens” is the most commonly studied regimen for 
feminization. Androgen reducing medications, from a variety of classes of drugs, have the effect 
of reducing either endogenous testosterone levels or testosterone activity, and thus diminishing 
masculine characteristics such as body hair. They minimize the dosage of estrogen needed to 
suppress testosterone, thereby reducing the risks associated with high-dose exogenous estrogen 
(Prior, Vigna, Watson, Diewold, & Robinow, 1986; Prior, Vigna, & Watson, 1989). 
Common anti-androgens include the following:
•	Spironolactone, an antihypertensive agent, directly inhibits testosterone secretion and andro-
gen binding to the androgen receptor. Blood pressure and electrolytes need to be monitored 
because of the potential for hyperkalemia.
•	Cyproterone acetate is a progestational compound with anti-androgenic properties. This 
medication is not approved in the United States because of concerns over potential hepato-
toxicity, but it is widely used elsewhere (De Cuypere et al., 2005).
•	GnRH agonists (e.g., goserelin, buserelin, triptorelin) are neurohormones that block the 
gonadtropin releasing hormone receptor, thus blocking the release of follicle stimulating 
hormone and luteinizing hormone. This leads to highly effective gonadal blockade. However, 
these medications are expensive and only available as injectables or implants. 
•	5-alpha reductase inhibitors (finasteride and dutasteride) block the conversion of testoster-
one to the more active agent, 5-alpha-dihydrotestosterone. These medications have beneficial 
effects on scalp hair loss, body hair growth, sebaceous glands, and skin consistency. 
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Cyproterone and spironolactone are the most commonly used anti-androgens and are likely the 
most cost-effective. 
Progestins
With the exception of cyproterone, the inclusion of progestins in feminizing hormone therapy is 
controversial (Oriel, 2000). Because progestins play a role in mammary development on a cellular 
level, some clinicians believe that these agents are necessary for full breast development (Basson & 
Prior, 1998; Oriel, 2000). However, a clinical comparison of feminization regimens with and without 
progestins found that the addition of progestins neither enhanced breast growth nor lowered 
serum levels of free testosterone (Meyer III et al., 1986). There are concerns regarding potential 
adverse effects of progestins, including depression, weight gain, and lipid changes (Meyer III et al., 
1986; Tangpricha et al., 2003). Progestins (especially medroxyprogesterone) are also suspected to 
increase breast cancer risk and cardiovascular risk in women (Rossouw et al., 2002). Micronized 
progesterone may be better tolerated and have a more favorable impact on the lipid profile than 
medroxyprogesterone does (de Lignières, 1999; Fitzpatrick, Pace, & Wiita, 2000). 
Regimens for masculinizing hormone therapy (FtM)
Testosterone
Testosterone generally can be given orally, transdermally, or parenterally (IM), although buccal 
and implantable preparations are also available. Oral testosterone undecanoate, available outside 
the United States, results in lower serum testosterone levels than non-oral preparations and 
has limited efficacy in suppressing menses (Feldman, 2005, April; Moore et al., 2003). Because 
intramuscular testosterone cypionate or enanthate are often administered every 2-4 weeks, some 
patients may notice cyclic variation in effects (e.g., fatigue and irritability at the end of the injection 
cycle, aggression or expansive mood at the beginning of the injection cycle), as well as more time 
outside the normal physiologic levels (Jockenhövel, 2004). This may be mitigated by using a lower 
but more frequent dosage schedule or by using a daily transdermal preparation (Dobs et al., 1999; 
Jockenhövel, 2004; Nieschlag et al., 2004). Intramuscular testosterone undecanoate (not currently 
available in the United States) maintains stable, physiologic testosterone levels over approximately 
12 weeks and has been effective in both the setting of hypogonadism and in FtM individuals 
(Mueller, Kiesewetter, Binder, Beckmann, & Dittrich, 2007; Zitzmann, Saad, & Nieschlag, 2006). 
There is evidence that transdermal and intramuscular testosterone achieve similar masculinizing 
results, although the timeframe may be somewhat slower with transdermal preparations (Feldman, 
2005, April). Especially as patients age, the goal is to use the lowest dose needed to maintain the 
desired clinical result, with appropriate precautions being made to maintain bone density. 
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Other agents
Progestins, most commonly medroxyprogesterone, can be used for a short period of time to assist 
with menstrual cessation early in hormone therapy. GnRH agonists can be used similarly, as well as 
for refractory uterine bleeding in patients without an underlying gynecological abnormality.
Bioidentical and compounded hormones
As discussion surrounding the use of bioidentical hormones in postmenopausal hormone 
replacement has heightened, interest has also increased in the use of similar compounds in 
feminizing/masculinizing hormone therapy. There is no evidence that custom compounded 
bioidentical hormones are safer or more effective than government agency-approved bioidentical 
hormones (Sood, Shuster, Smith, Vincent, & Jatoi, 2011). Therefore, it has been advised by the 
North American Menopause Society (2010) and others to assume that, whether the hormone is 
from a compounding pharmacy or not, if the active ingredients are similar, it should have a similar 
side-effect profile. WPATH concurs with this assessment.
IX 
Reproductive Health 
Many transgender, transsexual, and gender nonconforming people will want to have children. 
Because feminizing/masculinizing hormone therapy limits fertility (Darney, 2008; Zhang, Gu, 
Wang, Cui, & Bremner, 1999), it is desirable for patients to make decisions concerning fertility 
before starting hormone therapy or undergoing surgery to remove/alter their reproductive organs. 
Cases are known of people who received hormone therapy and genital surgery and later regretted 
their inability to parent genetically related children (De Sutter, Kira, Verschoor, & Hotimsky, 2002). 
Health care professionals – including mental health professionals recommending hormone therapy 
or surgery, hormone-prescribing physicians, and surgeons – should discuss reproductive options 
with patients prior to initiation of these medical treatments for gender dysphoria. These discussions 
should occur even if patients are not interested in these issues at the time of treatment, which may 
be more common for younger patients (De Sutter, 2009). Early discussions are desirable, but not 
always possible. If an individual has not had complete sex reassignment surgery, it may be possible 
to stop hormones long enough for natal hormones to recover, allowing the production of mature 
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gametes (Payer, Meyer III, & Walker, 1979; Van den Broecke, Van der Elst, Liu, Hovatta, & Dhont, 
2001). 
Besides debate and opinion papers, very few research papers have been published on the 
reproductive health issues of individuals receiving different medical treatments for gender 
dysphoria. Another group who faces the need to preserve reproductive function in light of loss or 
damage to their gonads are people with malignancies that require removal of reproductive organs 
or use of damaging radiation or chemotherapy. Lessons learned from that group can be applied to 
people treated for gender dysphoria.
MtF patients, especially those who have not already reproduced, should be informed about sperm 
preservation options and encouraged to consider banking their sperm prior to hormone therapy. 
In a study examining testes that were exposed to high-dose estrogen (Payer et al., 1979), findings 
suggest that stopping estrogen may allow the testes to recover. In an article reporting on the 
opinions of MtF individuals towards sperm freezing (De Sutter et al., 2002), the vast majority of 
121 survey respondents felt that the availability of freezing sperm should be discussed and offered 
by the medical world. Sperm should be collected before hormone therapy or after stopping the 
therapy until the sperm count rises again. Cryopreservation should be discussed even if there is poor 
semen quality. In adults with azoospermia, a testicular biopsy with subsequent cryopreservation of 
biopsied material for sperm is possible, but may not be successful. 
Reproductive options for FtM patients might include oocyte (egg) or embryo freezing. The frozen 
gametes and embryo could later be used with a surrogate woman to carry to pregnancy. Studies of 
women with polycystic ovarian disease suggest that the ovary can recover in part from the effects of 
high testosterone levels (Hunter & Sterrett, 2000). Stopping the testosterone briefly might allow for 
ovaries to recover enough to release eggs; success likely depends on the patient’s age and duration 
of testosterone treatment. While not systematically studied, some FtM individuals are doing exactly 
that, and some have been able to become pregnant and deliver children (More, 1998). 
Patients should be advised that these techniques are not available everywhere and can be very costly. 
Transsexual, transgender, and gender nonconforming people should not be refused reproductive 
options for any reason.
A special group of individuals are prepubertal or pubertal adolescents who will never develop 
reproductive function in their natal sex due to blockers or cross gender hormones. At this time 
there is no technique for preserving function from the gonads of these individuals. 
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X 
Voice and Communication Therapy 
Communication, both verbal and nonverbal, is an important aspect of human behavior and gender 
expression. Transsexual, transgender, and gender nonconforming people might seek the assistance 
of a voice and communication specialist to develop vocal characteristics (e.g., pitch, intonation, 
resonance, speech rate, phrasing patterns) and non-verbal communication patterns (e.g., gestures, 
posture/movement, facial expressions) that facilitate comfort with their gender identity. Voice and 
communication therapy may help to alleviate gender dysphoria and be a positive and motivating 
step towards achieving one’s goals for gender role expression. 
Competency of Voice and Communication 
Specialists Working with Transsexual, Transgender, 
and Gender Nonconforming Clients 
Specialists may include speech-language pathologists, speech therapists, and speech-voice 
clinicians. In most countries the professional association for speech-language pathologists 
requires specific qualifications and credentials for membership. In some countries the government 
regulates practice through licensing, certification, or registration processes (American Speech-
Language-Hearing Association, 2011; Canadian Association of Speech-Language Pathologists and 
Audiologists; Royal College of Speech Therapists, United Kingdom; Speech Pathology Australia; 
Vancouver Coastal Health, Vancouver, British Columbia, Canada). 
The following are recommended minimum credentials for voice and communication specialists 
working with transsexual, transgender, and gender nonconforming clients:
1. Specialized training and competence in the assessment and development of communication 
skills in transsexual, transgender, and gender nonconforming clients.
2. A basic understanding of transgender health, including hormonal and surgical treatments for 
feminization/masculinization and trans-specific psychosocial issues as outlined in the SOC; 
and familiarity with basic sensitivity protocols such as the use of preferred gender pronoun and 
name (Canadian Association of Speech-Language Pathologists and Audiologists; Royal College 
of Speech Therapists, United Kingdom; Speech Pathology Australia).
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3. Continuing education in the assessment and development of communication skills in trans-
sexual, transgender, and gender nonconforming clients. This may include attendance at profes-
sional meetings, workshops, or seminars; participation in research related to gender identity 
issues; independent study; or mentoring from an experienced, certified clinician. 
Other professionals such as vocal coaches, theatre professionals, singing teachers, and movement 
experts may play a valuable adjunct role. Such professionals will ideally have experience working 
with, or be actively collaborating with, speech-language pathologists. 
Assessment and Treatment Considerations
The overall purpose of voice and communication therapy is to help clients adapt their voice and 
communication in a way that is both safe and authentic, resulting in communication patterns 
that clients feel are congruent with their gender identity and that reflect their sense of self (Adler, 
Hirsch, & Mordaunt, 2006). It is essential that voice and communication specialists be sensitive 
to individual communication preferences. Communication – style, voice, choice of language, etc. 
– is personal. Individuals should not be counseled to adopt behaviors with which they are not 
comfortable or which do not feel authentic. Specialists can best serve their clients by taking the time 
to understand a person’s gender concerns and goals for gender role expression (American Speech-
Language-Hearing Association, 2011; Canadian Association of Speech-Language Pathologists and 
Audiologists; Royal College of Speech Therapists, United Kingdom; Speech Pathology Australia).  
Individuals may choose the communication behaviors that they wish to acquire in accordance with 
their gender identity. These decisions are also informed and supported by the knowledge of the 
voice and communication specialist and by the assessment data for a specific client (Hancock, 
Krissinger, & Owen, 2010). Assessment includes a client’s self-evaluation and a specialist’s 
evaluation of voice, resonance, articulation, spoken language, and non-verbal communication 
(Adler et al., 2006; Hancock et al., 2010). 
Voice and communication treatment plans are developed by considering the available research 
evidence, the clinical knowledge and experience of the specialist, and the client’s own goals and 
values (American Speech-Language-Hearing Association, 2011; Canadian Association of Speech-
Language Pathologists and Audiologists; Royal College of Speech Therapists, United Kingdom; 
Speech Pathology Australia; Vancouver Coastal Health, Vancouver, British Columbia, Canada). 
Targets of treatment typically include pitch, intonation, loudness and stress patterns, voice quality, 
resonance, articulation, speech rate and phrasing, language, and non-verbal communication (Adler 
et al., 2006; Davies & Goldberg, 2006; de Bruin, Coerts, & Greven, 2000; Gelfer, 1999; McNeill, 2006; 
Oates & Dacakis, 1983). Treatment may involve individual and/or group sessions. The frequency 
and duration of treatment will vary according to a client’s needs. Existing protocols for voice and 
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communication treatment can be considered in developing an individualized therapy plan (Carew, 
Dacakis, & Oates, 2007; Dacakis, 2000; Davies & Goldberg, 2006; Gelfer, 1999; McNeill, Wilson, 
Clark, & Deakin, 2008; Mount & Salmon, 1988). 
Feminizing or masculinizing the voice involves non-habitual use of the voice production mechanism. 
Prevention measures are necessary to avoid the possibility of vocal misuse and long-term vocal 
damage. All voice and communication therapy services should therefore include a vocal health 
component (Adler et al., 2006).
Vocal Health Considerations after Voice Feminization Surgery
As noted in section XI, some transsexual, transgender, and gender nonconforming people will 
undergo voice feminization surgery. (Voice deepening can be achieved through masculinizing 
hormone therapy, but feminizing hormones do not have an impact on the adult MtF voice.) There 
are varying degrees of satisfaction, safety, and long-term improvement in patients who have had 
such surgery. It is recommended that individuals undergoing voice feminization surgery also 
consult a voice and communication specialist to maximize the surgical outcome, help protect 
vocal health, and learn non-pitch related aspects of communication. Voice surgery procedures 
should include follow-up sessions with a voice and communication specialist who is licensed and/
or credentialed by the board responsible for speech therapists/speech-language pathologists in 
that country (Kanagalingam et al., 2005; Neumann & Welzel, 2004).
XI 
Surgery
Sex Reassignment Surgery Is Effective and Medically Necessary
Surgery – particularly genital surgery – is often the last and the most considered step in the treatment 
process for gender dysphoria. While many transsexual, transgender, and gender nonconforming 
individuals find comfort with their gender identity, role, and expression without surgery, for many 
others surgery is essential and medically necessary to alleviate their gender dysphoria (Hage 
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& Karim, 2000). For the latter group, relief from gender dysphoria cannot be achieved without 
modification of their primary and/or secondary sex characteristics to establish greater congruence 
with their gender identity. Moreover, surgery can help patients feel more at ease in the presence of 
sex partners or in venues such as physicians’ offices, swimming pools, or health clubs. In some 
settings, surgery might reduce risk of harm in the event of arrest or search by police or other 
authorities.
Follow-up studies have shown an undeniable beneficial effect of sex reassignment surgery on 
postoperative outcomes such as subjective well being, cosmesis, and sexual function (De Cuypere 
et al., 2005; Gijs & Brewaeys, 2007; Klein & Gorzalka, 2009; Pfäfflin & Junge, 1998). Additional 
information on the outcomes of surgical treatments are summarized in Appendix D.
Ethical Questions Regarding Sex Reassignment Surgery
In ordinary surgical practice, pathological tissues are removed to restore disturbed functions, or 
alterations are made to body features to improve a patient’s self image. Some people, including 
some health professionals, object on ethical grounds to surgery as a treatment for gender dysphoria, 
because these conditions are thought not to apply. 
It is important that health professionals caring for patients with gender dysphoria feel comfortable 
about altering anatomically normal structures. In order to understand how surgery can alleviate the 
psychological discomfort and distress of individuals with gender dysphoria, professionals need to 
listen to these patients discuss their symptoms, dilemmas, and life histories. The resistance against 
performing surgery on the ethical basis of “above all do no harm” should be respected, discussed, 
and met with the opportunity to learn from patients themselves about the psychological distress 
of having gender dysphoria and the potential for harm caused by denying access to appropriate 
treatments. 
Genital and breast/chest surgical treatments for gender dysphoria are not merely another set of 
elective procedures. Typical elective procedures involve only a private mutually consenting contract 
between a patient and a surgeon. Genital and breast/chest surgeries as medically necessary 
treatments for gender dysphoria are to be undertaken only after assessment of the patient by 
qualified mental health professionals, as outlined in section VII of the SOC. These surgeries may 
be performed once there is written documentation that this assessment has occurred and that 
the person has met the criteria for a specific surgical treatment. By following this procedure, 
mental health professionals, surgeons, and patients share responsibility for the decision to make 
irreversible changes to the body. 
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It is unethical to deny availability or eligibility for sex reassignment surgeries solely on the basis of 
blood seropositivity for blood-borne infections such as HIV or hepatitis C or B.
Relationship of Surgeons with Mental Health 
Professionals, Hormone-Prescribing Physicians (if 
Applicable), and Patients (Informed Consent)
The role of a surgeon in the treatment of gender dysphoria is not that of a mere technician. Rather, 
conscientious surgeons will have insight into each patient’s history and the rationale that led to 
the referral for surgery. To that end, surgeons must talk at length with their patients and have 
close working relationships with other health professionals who have been actively involved in their 
clinical care. 
Consultation is readily accomplished when a surgeon practices as part of an interdisciplinary health 
care team. In the absence of this, a surgeon must be confident that the referring mental health 
professional(s), and if applicable the physician who prescribes hormones, are competent in the 
assessment and treatment of gender dysphoria, because the surgeon is relying heavily on their 
expertise. 
Once a surgeon is satisfied that the criteria for specific surgeries have been met (as outlined below), 
surgical treatment should be considered and a preoperative surgical consultation should take place. 
During this consultation, the procedure and postoperative course should be extensively discussed 
with the patient. Surgeons are responsible for discussing all of the following with patients seeking 
surgical treatments for gender dysphoria:
•	The different surgical techniques available (with referral to colleagues who provide alternative 
options);
•	The advantages and disadvantages of each technique;
•	The limitations of a procedure to achieve “ideal” results; surgeons should provide a full range 
of before-and-after photographs of their own patients, including both successful and unsuc-
cessful outcomes; 
•	The inherent risks and possible complications of the various techniques; surgeons should 
inform patients of their own complication rates with each procedure. 
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These discussions are the core of the informed consent process, which is both an ethical and 
legal requirement for any surgical procedure. Ensuring that patients have a realistic expectation of 
outcomes is important in achieving a result that will alleviate their gender dysphoria.
All of this information should be provided to patients in writing, in a language in which they are 
fluent, and in graphic illustrations. Patients should receive the information in advance (possibly 
via the internet) and given ample time to review it carefully. The elements of informed consent 
should always be discussed face-to-face prior to the surgical intervention. Questions can then be 
answered and written informed consent can be provided by the patient. Because these surgeries are 
irreversibile, care should be taken to ensure that patients have sufficient time to absorb information 
fully before they are asked to provide informed consent. A minimum of 24 hours is suggested.
Surgeons should provide immediate aftercare and consultation with other physicians serving the 
patient in the future. Patients should work with their surgeon to develop an adequate aftercare plan 
for the surgery.
Overview of Surgical Procedures for the Treatment 
of Patients with Gender Dysphoria
For the male-to-female (MtF) patient, surgical procedures may include the following:
1. Breast/chest surgery: augmentation mammoplasty (implants/lipofilling);
2. Genital surgery: penectomy, orchiectomy, vaginoplasty, clitoroplasty, vulvoplasty;
3. Non-genital, non-breast surgical interventions: facial feminization surgery, liposuction, lipofill-
ing, voice surgery, thyroid cartilage reduction, gluteal augmentation (implants/lipofilling), hair 
reconstruction, and various aesthetic procedures.
For the female-to-male (FtM) patient, surgical procedures may include the following:
1. Breast/chest surgery: subcutaneous mastectomy, creation of a male chest;
2. Genital surgery: hysterectomy/ovariectomy, reconstruction of the fixed part of the urethra, 
which can be combined with a metoidioplasty or with a phalloplasty (employing a pedicled or 
free vascularized flap), vaginectomy, scrotoplasty, and implantation of erection and/or testicu-
lar prostheses;
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3. Non-genital, non-breast surgical interventions: voice surgery (rare), liposuction, lipofilling, pec-
toral implants, and various aesthetic procedures.
Reconstructive Versus Aesthetic Surgery
The question of whether sex reassignment surgery should be considered “aesthetic” surgery or 
“reconstructive” surgery is pertinent not only from a philosophical point of view, but also from a 
financial point of view. Aesthetic or cosmetic surgery is mostly regarded as not medically necessary 
and therefore is typically paid for entirely by the patient. In contrast, reconstructive procedures 
are considered medically necessary – with unquestionable therapeutic results – and thus paid for 
partially or entirely by national health systems or insurance companies.
Unfortunately, in the field of plastic and reconstructive surgery (both in general and specifically 
for gender-related surgeries), there is no clear distinction between what is purely reconstructive 
and what is purely cosmetic. Most plastic surgery procedures actually are a mixture of both 
reconstructive and cosmetic components.
While most professionals agree that genital surgery and mastectomy cannot be considered purely 
cosmetic, opinions diverge as to what degree other surgical procedures (e.g., breast augmentation, 
facial feminization surgery) can be considered purely reconstructive. Although it may be much 
easier to see a phalloplasty or a vaginoplasty as an intervention to end lifelong suffering, for certain 
patients an intervention like a reduction rhinoplasty can have a radical and permanent effect on 
their quality of life, and therefore is much more medically necessary than for somebody without 
gender dysphoria.
Criteria for Surgeries
As for all of the SOC, the criteria for initiation of surgical treatments for gender dysphoria were 
developed to promote optimal patient care. While the SOC allow for an individualized approach 
to best meet a patient’s health care needs, a criterion for all breast/chest and genital surgeries 
is documentation of persistent gender dysphoria by a qualified mental health professional. For 
some surgeries, additional criteria include preparation and treatment consisting of feminizing/
masculinizing hormone therapy and one year of continuous living in a gender role that is congruent 
with one’s gender identity. 
These criteria are outlined below. Based on the available evidence and expert clinical consensus, 
different recommendations are made for different surgeries. 
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The SOC do not specify an order in which different surgeries should occur. The number and 
sequence of surgical procedures may vary from patient to patient, according to their clinical needs. 
Criteria for breast/chest surgery (one referral) 
Criteria for mastectomy and creation of a male chest in FtM patients:
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC for children and adolescents);
4. If significant medical or mental health concerns are present, they must be reasonably well 
controlled.
Hormone therapy is not a pre-requisite.
Criteria for breast augmentation (implants/lipofilling) in MtF patients:
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC for children and adolescents);
4. If significant medical or mental health concerns are present, they must be reasonably well 
controlled.
Although not an explicit criterion, it is recommended that MtF patients undergo feminizing 
hormone therapy (minimum 12 months) prior to breast augmentation surgery. The purpose is to 
maximize breast growth in order to obtain better surgical (aesthetic) results. 
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Criteria for genital surgery (two referrals) 
The criteria for genital surgery are specific to the type of surgery being requested.
Criteria for hysterectomy and ovariectomy in FtM patients and for orchiectomy in MtF patients: 
1. Persistent, well documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country; 
4. If significant medical or mental health concerns are present, they must be well controlled.
5. 12 continuous months of hormone therapy as appropriate to the patient’s gender goals (un-
less the patient has a medical contraindication or is otherwise unable or unwilling to take 
hormones).
The aim of hormone therapy prior to gonadectomy is primarily to introduce a period of reversible 
estrogen or testosterone suppression, before the patient undergoes irreversible surgical intervention. 
These criteria do not apply to patients who are having these procedures for medical indications 
other than gender dysphoria.
Criteria for metoidioplasty or phalloplasty in FtM patients and for vaginoplasty in MtF patients: 
1. Persistent, well documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country; 
4. If significant medical or mental health concerns are present, they must be well controlled;
5. 12 continuous months of hormone therapy as appropriate to the patient’s gender goals (un-
less the patient has a medical contraindication or is otherwise unable or unwilling to take 
hormones).
6. 12 continuous months of living in a gender role that is congruent with their gender identity; 
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Although not an explicit criterion, it is recommended that these patients also have regular visits 
with a mental health or other medical professional. 
Rationale for a preoperative, 12-month experience of living in an identity-congruent gender role:
The criterion noted above for some types of genital surgeries – i.e., that patients engage in 
12 continuous months of living in a gender role that is congruent with their gender identity – is 
based on expert clinical consensus that this experience provides ample opportunity for patients to 
experience and socially adjust in their desired gender role, before undergoing irreversible surgery. 
As noted in section VII, the social aspects of changing one’s gender role are usually challenging 
– often more so than the physical aspects. Changing gender role can have profound personal 
and social consequences, and the decision to do so should include an awareness of what the 
familial, interpersonal, educational, vocational, economic, and legal challenges are likely to be, so 
that people can function successfully in their gender role. Support from a qualified mental health 
professional and from peers can be invaluable in ensuring a successful gender role adaptation 
(Bockting, 2008).
The duration of 12 months allows for a range of different life experiences and events that may 
occur throughout the year (e.g., family events, holidays, vacations, season-specific work or school 
experiences). During this time, patients should present consistently, on a day-to-day basis and 
across all settings of life, in their desired gender role. This includes coming out to partners, family, 
friends, and community members (e.g., at school, work, other settings). 
Health professionals should clearly document a patient’s experience in the gender role in the 
medical chart, including the start date of living full time for those who are preparing for genital 
surgery. In some situations, if needed, health professionals may request verification that this 
criterion has been fulfilled: They may communicate with individuals who have related to the patient 
in an identity-congruent gender role, or request documentation of a legal name and/or gender 
marker change, if applicable. 
Surgery for People with Psychotic Conditions 
and Other Serious Mental Illnesses
When patients with gender dysphoria are also diagnosed with severe psychiatric disorders and 
impaired reality testing (e.g., psychotic episodes, bipolar disorder, dissociative identity disorder, 
borderline personality disorder), an effort must be made to improve these conditions with 
psychotropic medications and/or psychotherapy before surgery is contemplated. Reevaluation 
by a mental health professional qualified to assess and manage psychotic conditions should be 
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conducted prior to surgery, describing the patient’s mental status and readiness for surgery. It is 
preferable that this mental health professional be familiar with the patient. No surgery should be 
performed while a patient is actively psychotic (De Cuypere & Vercruysse, 2009). 
Competency of Surgeons Performing 
Breast/Chest or Genital Surgery
Physicians who perform surgical treatments for gender dsyphoria should be urologists, gynecologists, 
plastic surgeons, or general surgeons, and board-certified as such by the relevant national and/
or regional association. Surgeons should have specialized competence in genital reconstructive 
techniques as indicated by documented supervised training with a more experienced surgeon. 
Even experienced surgeons must be willing to have their surgical skills reviewed by their peers. An 
official audit of surgical outcomes and publication of these results would be greatly reassuring to 
both referring health professionals and patients. Surgeons should regularly attend professional 
meetings where new techniques are presented. The internet is often effectively used by patients to 
share information on their experience with surgeons and their teams.
Ideally, surgeons should be knowledgeable about more than one surgical technique for genital 
reconstruction so that they, in consultation with patients, can choose the ideal technique for each 
individual. Alternatively, if a surgeon is skilled in a single technique and this procedure is either not 
suitable for or desired by a patient, the surgeon should inform the patient about other procedures 
and offer referral to another appropriately skilled surgeon.
Breast/Chest Surgery Techniques and Complications
Although breast/chest appearance is an important secondary sex characteristic, breast presence or 
size is not involved in the legal definitions of sex and gender and is not necessary for reproduction. 
The performance of breast/chest operations for treatment of gender dysphoria should be considered 
with the same care as beginning hormone therapy, as both produce relatively irreversible changes 
to the body. 
For the MtF patient, a breast augmentation (sometimes called “chest reconstruction”) is not 
different from the procedure in a natal female patient. It is usually performed through implantation 
of breast prostheses and occasionally with the lipofilling technique. Infections and capsular fibrosis 
are rare complications of augmentation mammoplasty in MtF patients (Kanhai, Hage, Karim, & 
Mulder, 1999).
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For the FtM patient, a mastectomy or “male chest contouring” procedure is available. For many 
FtM patients, this is the only surgery undertaken. When the amount of breast tissue removed 
requires skin removal, a scar will result and the patient should be so informed. Complications 
of subcutaneous mastectomy can include nipple necrosis, contour irregularities, and unsightly 
scarring (Monstrey et al., 2008).
Genital Surgery Techniques and Complications
Genital surgical procedures for the MtF patient may include orchiectomy, penectomy, vaginoplasty, 
clitoroplasty, and labiaplasty. Techniques include penile skin inversion, pedicled colosigmoid 
transplant, and free skin grafts to line the neovagina. Sexual sensation is an important objective in 
vaginoplasty, along with creation of a functional vagina and acceptable cosmesis.
Surgical complications of MtF genital surgery may include complete or partial necrosis of the 
vagina and labia, fistulas from the bladder or bowel into the vagina, stenosis of the urethra, and 
vaginas that are either too short or too small for coitus. While the surgical techniques for creating 
a neovagina are functionally and aesthetically excellent, anorgasmia following the procedure has 
been reported, and a second stage labiaplasty may be needed for cosmesis (Klein & Gorzalka, 
2009; Lawrence, 2006). 
Genital surgical procedures for FtM patients may include hysterectomy, ovariectomy, salpingo-
oophorectomy, vaginectomy, metoidioplasty, scrotoplasty, urethroplasty, placement of testicular 
prostheses, and phalloplasty. For patients without former abdominal surgery, the laparoscopic 
technique for hysterectomy and salpingo-oophorectomy is recommended to avoid a lower-
abdominal scar. Vaginal access may be difficult as most patients are nulliparous and have often not 
experienced penetrative intercourse. Current operative techniques for phalloplasty are varied. The 
choice of techniques may be restricted by anatomical or surgical considerations and by a client’s 
financial considerations. If the objectives of phalloplasty are a neophallus of good appearance, 
standing micturition, sexual sensation, and/or coital ability, patients should be clearly informed 
that there are several separate stages of surgery and frequent technical difficulties, which may 
require additional operations. Even metoidioplasty, which in theory is a one-stage procedure for 
construction of a microphallus, often requires more than one operation. The objective of standing 
micturition with this technique can not always be ensured (Monstrey et al., 2009).
Complications of phalloplasty in FtMs may include frequent urinary tract stenoses and fistulas, 
and occasionally necrosis of the neophallus. Metoidioplasty results in a micropenis, without the 
capacity for standing urination. Phalloplasty, using a pedicled or a free vascularized flap, is a lengthy, 
multi-stage procedure with significant morbidity that includes frequent urinary complications and 
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unavoidable donor site scarring. For this reason, many FtM patients never undergo genital surgery 
other than hysterectomy and salpingo-oophorectomy (Hage & De Graaf, 1993).
Even patients who develop severe surgical complications seldom regret having undergone surgery. 
The importance of surgery can be appreciated by the repeated finding that quality of surgical results 
is one of the best predictors of the overall outcome of sex reassignment (Lawrence, 2006). 
Other Surgeries 
Other surgeries for assisting in body feminization include reduction thyroid chondroplasty 
(reduction of the Adam’s apple), voice modification surgery, suction-assisted lipoplasty (contour 
modeling) of the waist, rhinoplasty (nose correction), facial bone reduction, face-lift, and 
blepharoplasty (rejuvenation of the eyelid). Other surgeries for assisting in body masculinization 
include liposuction, lipofilling, and pectoral implants. Voice surgery to obtain a deeper voice is rare 
but may be recommended in some cases, such as when hormone therapy has been ineffective. 
Although these surgeries do not require referral by mental health professionals, such professionals 
can play an important role in assisting clients in making a fully informed decision about the timing 
and implications of such procedures in the context of the social transition.
Although most of these procedures are generally labeled “purely aesthetic,” these same operations 
in an individual with severe gender dysphoria can be considered medically necessary, depending on 
the unique clinical situation of a given patient’s condition and life situation. This ambiguity reflects 
reality in clinical situations, and allows for individual decisions as to the need and desirability of 
these procedures.
XII 
Postoperative Care and Follow-up
Long-term postoperative care and follow-up after surgical treatments for gender dysphoria are 
associated with good surgical and psychosocial outcomes (Monstrey et al., 2009). Follow-up is 
important to a patient’s subsequent physical and mental health and to a surgeon’s knowledge 
about the benefits and limitations of surgery. Surgeons who operate on patients coming from long 
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distances should include personal follow-up in their care plan and attempt to ensure affordable 
local long-term aftercare in their patients’ geographic region. 
Postoperative patients may sometimes exclude themselves from follow-up by specialty providers, 
including the hormone-prescribing physician (for patients receiving hormones), not recognizing 
that these providers are often best able to prevent, diagnose, and treat medical conditions that 
are unique to hormonally and surgically treated patients. The need for follow-up equally extends 
to mental health professionals, who may have spent a longer period of time with the patient than 
any other professional and therefore are in an excellent position to assist in any postoperative 
adjustment difficulties. Health professionals should stress the importance of postoperative follow-
up care with their patients and offer continuity of care.
Postoperative patients should undergo regular medical screening according to recommended 
guidelines for their age. This is discussed more in the next section.
XIII 
Lifelong Preventive and Primary Care
Transsexual, transgender, and gender nonconforming people need health care throughout their 
lives. For example, to avoid the negative secondary effects of having a gonadectomy at a relatively 
young age and/or receiving long-term, high-dose hormone therapy, patients need thorough medical 
care by providers experienced in primary care and transgender health. If one provider is not able to 
provide all services, ongoing communication among providers is essential.
Primary care and health maintenance issues should be addressed before, during, and after any 
possible changes in gender role and medical interventions to alleviate gender dysphoria. While 
hormone providers and surgeons play important roles in preventive care, every transsexual, 
transgender, and gender nonconforming person should partner with a primary care provider for 
overall health care needs (Feldman, 2007). 
General Preventive Health Care
Screening guidelines developed for the general population are appropriate for organ systems that 
are unlikely to be affected by feminizing/masculinizing hormone therapy. However, in areas such 
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as cardiovascular risk factors, osteoporosis, and some cancers (breast, cervical, ovarian, uterine, 
and prostate), such general guidelines may either over- or underestimate the cost-effectiveness of 
screening individuals who are receiving hormone therapy.
Several resources provide detailed protocols for the primary care of patients undergoing feminizing/
masculinizing hormone therapy, including therapy that is provided after sex reassignment surgeries 
(Center of Excellence for Transgender Health, UCSF, 2011; Feldman & Goldberg, 2006; Feldman, 
2007; Gorton, Buth, & Spade, 2005). Clinicians should consult their national evidence-based 
guidelines and discuss screening with their patients in light of the effects of hormone therapy on 
their baseline risk. 
Cancer Screening
Cancer screening of organ systems that are associated with sex can present particular medical 
and psychosocial challenges for transsexual, transgender, and gender nonconforming patients and 
their health care providers. In the absence of large-scale prospective studies, providers are unlikely 
to have enough evidence to determine the appropriate type and frequency of cancer screenings 
for this population. Over-screening results in higher health care costs, high false positive rates, 
and often unnecessary exposure to radiation and/or diagnostic interventions such as biopsies. 
Under-screening results in diagnostic delay for potentially treatable cancers. Patients may find 
cancer screening gender affirming (such as mammograms for MtF patients) or both physically 
and emotionally painful (such as Pap smears offer continuity of care for FtM patients).
Urogenital Care 
Gynecologic care may be necessary for transsexual, transgender, and gender nonconforming 
people of both sexes. For FtM patients, such care is needed predominantly for individuals who 
have not had genital surgery. For MtF patients, such care is needed after genital surgery. While 
many surgeons counsel patients regarding postoperative urogenital care, primary care clinicians 
and gynecologists should also be familiar with the special genital concerns of this population.
All MtF patients should receive counseling regarding genital hygiene, sexuality, and prevention of 
sexually transmitted infections; those who have had genital surgery should also be counseled on the 
need for regular vaginal dilation or penetrative intercourse in order to maintain vaginal depth and 
width (van Trotsenburg, 2009). Due to the anatomy of the male pelvis, the axis and the dimensions 
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of the neovagina differ substantially from those of a biologic vagina. This anatomic difference can 
affect intercourse if not understood by MtF patients and their partners (van Trotsenburg, 2009).
Lower urinary tract infections occur frequently in MtF patients who have had surgery because of 
the reconstructive requirements of the shortened urethra. In addition, these patients may suffer 
from functional disorders of the lower urinary tract; such disorders may be caused by damage of 
the autonomous nerve supply of the bladder floor during dissection between the rectum and the 
bladder, and by a change of the position of the bladder itself. A dysfunctional bladder (e.g., overactive 
bladder, stress or urge urinary incontinence) may occur after sex reassignment surgery (Hoebeke et 
al., 2005; Kuhn, Hiltebrand, & Birkhauser, 2007). 
Most FtM patients do not undergo vaginectomy (colpectomy). For patients who take masculinizing 
hormones, despite considerable conversion of testosterone to estrogens, atrophic changes of the 
vaginal lining can be observed regularly and may lead to pruritus or burning. Examination can be 
both physically and emotionally painful, but lack of treatment can seriously aggravate the situation. 
Gynecologists treating the genital complaints of FtM patients should be aware of the sensitivity 
that patients with a male gender identity and masculine gender expression might have around 
having genitals typically associated with the female sex. 
XIV 
Applicability of the Standards of Care to People 
Living in Institutional Environments
The SOC in their entirety apply to all transsexual, transgender, and gender nonconforming people, 
irrespective of their housing situation. People should not be discriminated against in their access 
to appropriate health care based on where they live, including institutional environments such as 
prisons or long-/intermediate-term health care facilities (Brown, 2009). Health care for transsexual, 
transgender, and gender nonconforming people living in an institutional environment should 
mirror that which would be available to them if they were living in a non-institutional setting within 
the same community. 
All elements of assessment and treatment as described in the SOC can be provided to people 
living in institutions (Brown, 2009). Access to these medically necessary treatments should not 
be denied on the basis of institutionalization or housing arrangements. If the in-house expertise 
of health professionals in the direct or indirect employ of the institution does not exist to assess 
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and/or treat people with gender dysphoria, it is appropriate to obtain outside consultation from 
professionals who are knowledgeable about this specialized area of health care.
People with gender dysphoria in institutions may also have co-existing mental health conditions 
(Cole et al., 1997). These conditions should be evaluated and treated appropriately.
People who enter an institution on an appropriate regimen of hormone therapy should be continued 
on the same, or similar, therapies and monitored according to the SOC.  A “freeze frame” approach 
is not considered appropriate care in most situations (Kosilek v. Massachusetts Department of 
Corrections/Maloney, C.A. No. 92-12820-MLW, 2002). People with gender dysphoria who are 
deemed appropriate for hormone therapy (following the SOC) should be started on such therapy. 
The consequences of abrupt withdrawal of hormones or lack of initiation of hormone therapy when 
medically necessary include a high likelihood of negative outcomes such as surgical self-treatment 
by autocastration, depressed mood, dysphoria, and/or suicidality (Brown, 2010).
Reasonable accommodations to the institutional environment can be made in the delivery of care 
consistent with the SOC, if such accommodations do not jeopardize the delivery of medically 
necessary care to people with gender dysphoria. An example of a reasonable accommodation is the 
use of injectable hormones, if not medically contraindicated, in an environment where diversion of 
oral preparations is highly likely (Brown, 2009). Denial of needed changes in gender role or access 
to treatments, including sex reassignment surgery, on the basis of residence in an institution are 
not reasonable accommodations under the SOC (Brown, 2010). 
Housing and shower/bathroom facilities for transsexual, transgender, and gender nonconforming 
people living in institutions should take into account their gender identity and role, physical status, 
dignity, and personal safety. Placement in a single-sex housing unit, ward, or pod on the sole basis 
of the appearance of the external genitalia may not be appropriate and may place the individual at 
risk for victimization (Brown, 2009). 
Institutions where transsexual, transgender, and gender nonconforming people reside and receive 
health care should monitor for a tolerant and positive climate to ensure that residents are not 
under attack by staff or other residents.  
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XV  
Applicability of the Standards of Care to People 
With Disorders of Sex Development
Terminology
The term disorder of sex development (DSD) refers to a somatic condition of atypical development 
of the reproductive tract (Hughes, Houk, Ahmed, Lee, & LWPES1/ESPE2 Consensus Group, 2006). 
DSDs include the condition that used to be called intersexuality. Although the terminology was 
changed to DSD during an international consensus conference in 2005 (Hughes et al., 2006), 
disagreement about language use remains. Some people object strongly to the “disorder” label, 
preferring instead to view these congenital conditions as a matter of diversity (Diamond, 2009) and 
to continue using the terms intersex or intersexuality. In the SOC, WPATH uses the term DSD in 
an objective and value-free manner, with the goal of ensuring that health professionals recognize 
this medical term and use it to access relevant literature as the field progresses. WPATH remains 
open to new terminology that will further illuminate the experience of members of this diverse 
population and lead to improvements in health care access and delivery. 
Rationale for Addition to the SOC
Previously, individuals with a DSD who also met the DSM-IV-TR’s behavioral criteria for Gender 
Identity Disorder (American Psychiatric Association, 2000) were excluded from that general 
diagnosis. Instead, they were categorized as having a “Gender Identity Disorder - Not Otherwise 
Specified.” They were also excluded from the WPATH Standards of Care. 
The current proposal for DSM-5 (www.dsm5.org) is to replace the term gender identity disorder with 
gender dysphoria. Moreover, the proposed changes to the DSM consider gender dysphoric people 
with a DSD to have a subtype of gender dysphoria. This proposed categorization – which explicitly 
differentiates between gender dysphoric individuals with and without a DSD – is justified: In people 
with a DSD, gender dysphoria differs in its phenomenological presentation, epidemiology, life 
trajectories, and etiology (Meyer-Bahlburg, 2009). 
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Adults with a DSD and gender dysphoria have increasingly come to the attention of health 
professionals. Accordingly, a brief discussion of their care is included in this version of the SOC.
Health History Considerations
Health professionals assisting patients with both a DSD and gender dysphoria need to be aware 
that the medical context in which such patients have grown up is typically very different from that 
of people without a DSD. 
Some people are recognized as having a DSD through the observation of gender-atypical genitals at 
birth. (Increasingly this observation is made during the prenatal period by way of imaging procedures 
such as ultrasound.) These infants then undergo extensive medical diagnostic procedures. After 
consultation among the family and health professionals – during which the specific diagnosis, 
physical and hormonal findings, and feedback from long-term outcome studies (Cohen-Kettenis, 
2005; Dessens, Slijper, & Drop, 2005; Jurgensen, Hiort, Holterhus, & Thyen, 2007; Mazur, 2005; 
Meyer-Bahlburg, 2005; Stikkelbroeck et al., 2003; Wisniewski, Migeon, Malouf, & Gearhart, 2004) 
are considered – the newborn is assigned a sex, either male or female. 
Other individuals with a DSD come to the attention of health professionals around the age of 
puberty through the observation of atypical development of secondary sex characteristics. This 
observation also leads to a specific medical evaluation. 
The type of DSD and severity of the condition has significant implications for decisions about a 
patient’s initial sex assignment, subsequent genital surgery, and other medical and psychosocial 
care (Meyer-Bahlburg, 2009). For instance, the degree of prenatal androgen exposure in individuals 
with a DSD has been correlated with the degree of masculinization of gender-related behavior 
(that is, gender role and expression); however, the correlation is only moderate, and considerable 
behavioral variability remains unaccounted for by prenatal androgen exposure (Jurgensen et al., 
2007; Meyer-Bahlburg, Dolezal, Baker, Ehrhardt, & New, 2006). Notably, a similar correlation of 
prenatal hormone exposure with gender identity has not been demonstrated (e.g., Meyer-Bahlburg 
et al., 2004). This is underlined by the fact that people with the same (core) gender identity can vary 
widely in the degree of masculinization of their gender-related behavior.  
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Assessment and Treatment of Gender Dysphoria 
in People with Disorders of Sex Development
Very rarely are individuals with a DSD identified as having gender dysphoria before a DSD diagnosis 
has been made. Even so, a DSD diagnosis is typically apparent with an appropriate history and basic 
physical exam – both of which are part of a medical evaluation for the appropriateness of hormone 
therapy or surgical interventions for gender dysphoria. Mental health professionals should ask 
their clients presenting with gender dysphoria to have a physical exam, particularly if they are not 
currently seeing a primary care (or other health care) provider. 
Most people with a DSD who are born with genital ambiguity do not develop gender dysphoria 
(e.g., Meyer-Bahlburg et al., 2004; Wisniewski et al., 2004). However, some people with a DSD 
will develop chronic gender dysphoria and even undergo a change in their birth-assigned sex and/
or their gender role (Meyer-Bahlburg, 2005; Wilson, 1999; Zucker, 1999). If there are persistent 
and strong indications that gender dysphoria is present, a comprehensive evaluation by clinicians 
skilled in the assessment and treatment of gender dysphoria is essential, irrespective of the patient’s 
age. Detailed recommendations have been published for conducting such an assessment and for 
making treatment decisions to address gender dysphoria in the context of a DSD (Meyer-Bahlburg, 
in press). Only after thorough assessment should steps be taken in the direction of changing a 
patient’s birth-assigned sex or gender role. 
Clinicians assisting these patients with treatment options to alleviate gender dysphoria may profit 
from the insights gained from providing care to patients without a DSD (Cohen-Kettenis, 2010). 
However, certain criteria for treatment (e.g., age, duration of experience with living in the desired 
gender role) are usually not routinely applied to people with a DSD; rather, the criteria are interpreted 
in light of a patient’s specific situation (Meyer-Bahlburg, in press). In the context of a DSD, changes 
in birth-assigned sex and gender role have been made at any age between early elementary-school 
age and middle adulthood. Even genital surgery may be performed much earlier in these patients 
than in gender dysphoric individuals without a DSD if the surgery is well justified by the diagnosis, 
by the evidence-based gender-identity prognosis for the given syndrome and syndrome severity, 
and by the patient’s wishes. 
One reason for these treatment differences is that genital surgery in individuals with a DSD is quite 
common in infancy and adolescence. Infertility may already be present due to either early gonadal 
failure or to gonadectomy because of a malignancy risk. Even so, it is advisable for patients with a 
DSD to undergo a full social transition to another gender role only if there is a long-standing history 
of gender-atypical behavior, and if gender dysphoria and/or the desire to change one’s gender role 
has been strong and persistent for a considerable period of time. Six months is the time period of 
full symptom expression required for the application of the gender dysphoria diagnosis proposed 
for DSM-5 (Meyer-Bahlburg, in press).
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Additional Resources 
The gender-relevant medical histories of people with a DSD are often complex. Their histories may 
include a great variety of inborn genetic, endocrine, and somatic atypicalities, as well as various 
hormonal, surgical, and other medical treatments. For this reason, many additional issues need 
to be considered in the psychosocial and medical care of such patients, regardless of the presence 
of gender dysphoria. Consideration of these issues is beyond what can be covered in the SOC. 
The interested reader is referred to existing publications (e.g., Cohen-Kettenis & Pfäfflin, 2003; 
Meyer-Bahlburg, 2002, 2008). Some families and patients also find it useful to consult or work with 
community support groups.
There is a very substantial medical literature on the medical management of patients with a DSD. 
Much of this literature has been produced by high-level specialists in pediatric endocrinology and 
urology, with input from specialized mental health professionals, especially in the area of gender. 
Recent international consensus conferences have addressed evidence-based care guidelines 
(including issues of gender and of genital surgery) for DSD in general (Hughes et al., 2006) and 
specifically for Congenital Adrenal Hyperplasia (Joint LWPES/ESPE CAH Working Group et al., 
2002; Speiser et al., 2010). Others have addressed the research needs for DSD in general (Meyer-
Bahlburg & Blizzard, 2004) and for selected syndromes such as 46,XXY (Simpson et al., 2003). 
 ... 
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APPENDIX A 
GLOSSARY 
Terminology in the area of health care for transsexual, transgender, and gender nonconforming people 
is rapidly evolving; new terms are being introduced, and the definitions of existing terms are changing. 
Thus, there is often misunderstanding, debate, or disagreement about language in this field. Terms that 
may be unfamiliar or that have specific meanings in the SOC are defined below for the purpose of this 
document only. Others may adopt these definitions, but WPATH acknowledges that these terms may 
be defined differently in different cultures, communities, and contexts. 
WPATH also acknowledges that many terms used in relation to this population are not ideal. For 
example, the terms transsexual and transvestite – and, some would argue, the more recent term 
transgender – have been applied to people in an objectifying fashion. Yet such terms have been more 
or less adopted by many people who are making their best effort to make themselves understood. 
By continuing to use these terms, WPATH intends only to ensure that concepts and processes are 
comprehensible, in order to facilitate the delivery of quality health care to transsexual, transgender, and 
gender nonconforming people. WPATH remains open to new terminology that will further illuminate 
the experience of members of this diverse population and lead to improvements in health care access 
and delivery.  
Bioidentical hormones:  Hormones that are structurally identical to those found in the human body 
(ACOG Committee of Gynecologic Practice, 2005). The hormones used in bioidentical hormone 
therapy (BHT) are generally derived from plant sources and are structurally similar to endogenous 
human hormones, but they need to be commercially processed to become bioidentical.
Bioidentical compounded hormone therapy (BCHT):  Use of hormones that are prepared, mixed, 
assembled, packaged, or labeled as a drug by a pharmacist and custom-made for a patient according to 
a physician’s specifications. Government drug agency approval is not possible for each compounded 
product made for an individual consumer.
Crossdressing (transvestism): Wearing clothing and adopting a gender role presentation that, in a 
given culture, is more typical of the other sex.
Disorders of sex development (DSD):  Congenital conditions in which the development of 
chromosomal, gonadal, or anatomic sex is atypical. Some people strongly object to the “disorder” 
label and instead view these conditions as a matter of diversity (Diamond, 2009), preferring the terms 
intersex and intersexuality. 
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Female-to-Male (FtM):  Adjective to describe individuals assigned female at birth who are changing 
or who have changed their body and/or gender role from birth-assigned female to a more masculine 
body or role.
Gender dysphoria:  Distress that is caused by a discrepancy between a person’s gender identity and 
that person’s sex assigned at birth (and the associated gender role and/or primary and secondary sex 
characteristics) (Fisk, 1974; Knudson, De Cuypere, & Bockting, 2010b). 
Gender identity: A person’s intrinsic sense of being male (a boy or a man), female (a girl or woman), or 
an alternative gender (e.g., boygirl, girlboy, transgender, genderqueer, eunuch) (Bockting, 1999; Stoller, 
1964).
Gender identity disorder:  Formal diagnosis set forth by the Diagnostic Statistical Manual of Mental 
Disorders, 4th Edition, Text Rev (DSM IV-TR) (American Psychiatric Association, 2000). Gender identity 
disorder is characterized by a strong and persistent cross-gender identification and a persistent 
discomfort with one’s sex or sense of inappropriateness in the gender role of that sex, causing clinically 
significant distress or impairment in social, occupational, or other important areas of functioning.
Gender nonconforming:  Adjective to describe individuals whose gender identity, role, or expression 
differs from what is normative for their assigned sex in a given culture and historical period.
Gender role or expression:  Characteristics in personality, appearance, and behavior that in a given 
culture and historical period are designated as masculine or feminine (that is, more typical of the male 
or female social role) (Ruble, Martin, & Berenbaum, 2006). While most individuals present socially in 
clearly masculine or feminine gender roles, some people present in an alternative gender role such as 
genderqueer or specifically transgender. All people tend to incorporate both masculine and feminine 
characteristics in their gender expression in varying ways and to varying degrees (Bockting, 2008).
Genderqueer:  Identity label that may be used by individuals whose gender identity and/or role does 
not conform to a binary understanding of gender as limited to the categories of man or woman, male 
or female (Bockting, 2008).
Internalized Transphobia:  Discomfort with one’s own transgender feelings or identity as a result of 
internalizing society’s normative gender expectations.
Male-to-Female (MtF):  Adjective to describe individuals assigned male at birth who are changing or 
who have changed their body and/or gender role from birth-assigned male to a more feminine body 
or role.
Natural hormones:  Hormones that are derived from natural sources such as plants or animals. Natural 
hormones may or may not be bioidentical. 
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Sex:  Sex is assigned at birth as male or female, usually based on the appearance of the external 
genitalia. When the external genitalia are ambiguous, other components of sex (internal genitalia, 
chromosomal and hormonal sex) are considered in order to assign sex (Grumbach, Hughes, & Conte, 
2003; MacLaughlin & Donahoe, 2004; Money & Ehrhardt, 1972; Vilain, 2000). For most people, gender 
identity and expression are consistent with their sex assigned at birth; for transsexual, transgender, and 
gender nonconforming individuals, gender identity or expression differ from their sex assigned at birth.
Sex reassignment surgery (gender affirmation surgery):  Surgery to change primary and/or secondary 
sex characteristics to affirm a person’s gender identity. Sex reassignment surgery can be an important 
part of medically necessary treatment to alleviate gender dysphoria. 
Transgender:  Adjective to describe a diverse group of individuals who cross or transcend culturally-
defined categories of gender. The gender identity of transgender people differs to varying degrees from 
the sex they were assigned at birth (Bockting, 1999).
Transition:  Period of time when individuals change from the gender role associated with their sex 
assigned at birth to a different gender role. For many people, this involves learning how to live socially 
in another gender role; for others this means finding a gender role and expression that is most 
comfortable for them. Transition may or may not include feminization or masculinization of the body 
through hormones or other medical procedures. The nature and duration of transition is variable and 
individualized.
Transsexual:  Adjective (often applied by the medical profession) to describe individuals who seek to 
change or who have changed their primary and/or secondary sex characteristics through femininizing 
or masculinizing medical interventions (hormones and/or surgery), typically accompanied by a 
permanent change in gender role.
APPENDIX B 
OVERVIEW OF MEDICAL RISKS OF HORMONE THERAPY 
The risks outlined below are based on two comprehensive, evidence-based literature reviews of 
masculinizing/feminizing hormone therapy (Feldman & Safer, 2009; Hembree et al., 2009), along 
with a large cohort study (Asscheman et al., 2011). These reviews can serve as detailed references 
for providers, along with other widely recognized, published clinical materials (e.g., Dahl et al., 2006; 
Ettner et al., 2007). 
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Risks of Feminizing Hormone Therapy (MtF)
Likely increased risk:
Venous thromboembolic disease
•	Estrogen use increases the risk of venous thromboembolic events (VTE), particularly in patients 
who are over age 40, smokers, highly sedentary, obese, and who have underlying thrombophilic 
disorders. 
•	This risk is increased with the additional use of third generation progestins. 
•	This risk is decreased with use of the transdermal (versus oral) route of estradiol administration, 
which is recommended for patients at higher risk of VTE.
Cardiovascular, cerebrovascular disease
•	Estrogen use increases the risk of cardiovascular events in patients over age 50 with underlying 
cardiovascular risk factors. Additional progestin use may increase this risk.
Lipids
•	Oral estrogen use may markedly increase triglycerides in patients, increasing the risk of pancreati-
tis and cardiovascular events.
•	Different routes of administration will have different metabolic effects on levels of HDL choles-
terol, LDL cholesterol and lipoprotein(a).
•	In general, clinical evidence suggests that MtF patients with pre-existing lipid disorders may ben-
efit from the use of transdermal rather than oral estrogen.  
Liver/gallbladder
•	Estrogen and cyproterone acetate use may be associated with transient liver enzyme elevations 
and, rarely, clinical hepatotoxicity.
•	Estrogen use increases the risk of cholelithiasis (gall stones) and subsequent cholecystectomy.
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Possible increased risk:
Type 2 diabetes mellitus
•	Feminizing hormone therapy, particularly estrogen, may increase the risk of type 2 diabetes, par-
ticularly among patients with a family history of diabetes or other risk factors for this disease.
Hypertension
•	Estrogen use may increase blood pressure, but the effect on incidence of overt hypertension is 
unknown.
•	Spironolactone reduces blood pressure and is recommended for at-risk or hypertensive patients 
desiring feminization.
Prolactinoma
•	Estrogen use increases the risk of hyperprolactinemia among MtF patients in the first year of 
treatment, but this risk is unlikely thereafter. 
•	High-dose estrogen use may promote the clinical appearance of preexisting but clinically unap-
parent prolactinoma.
Inconclusive or no increased risk:
Items in this category include those that may present risk, but for which the evidence is so minimal that 
no clear conclusion can be reached. 
Breast cancer
•	MtF persons who have taken feminizing hormones do experience breast cancer, but it is un-
known how their degree of risk compares to that of persons born with female genitalia.
•	Longer duration of feminizing hormone exposure (i.e., number of years taking estrogen prepara-
tions), family history of breast cancer, obesity (BMI >35), and the use of progestins likely influ-
ence the level of risk.
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Other side effects of feminizing therapy:
The following effects may be considered minor or even desired, depending on the patient, but are 
clearly associated with feminizing hormone therapy.
Fertility and sexual function
•	Feminizing hormone therapy may impair fertility.
•	Feminizing hormone therapy may decrease libido.
•	Feminizing hormone therapy reduces nocturnal erections, with variable impact on sexually stimu-
lated erections.
Risks of anti-androgen medications:
Feminizing hormone regimens often include a variety of agents that affect testosterone production or 
action. These include GnRH agonists, progestins (including cyproterone acetate), spironolactone, and 
5-alpha reductase inhibitors. An extensive discussion of the specific risks of these agents is beyond the 
scope of the SOC. However, both spironolactone and cyproterone acetate are widely used and deserve 
some comment. 
Cyproterone acetate is a progestational compound with anti-androgenic properties (Gooren, 2005; Levy 
et al., 2003). Although widely used in Europe, it is not approved for use in the United States because of 
concerns about hepatotoxicity (Thole, Manso, Salgueiro, Revuelta, & Hidalgo, 2004). Spironolactone 
is commonly used as an anti-androgen in feminizing hormone therapy, particularly in regions where 
cyproterone is not approved for use (Dahl et al., 2006; Moore et al., 2003; Tangpricha et al., 2003). 
Spironolactone has a long history of use in treating hypertension and congestive heart failure. Its 
common side effects include hyperkalemia, dizziness, and gastrointestinal symptoms (Physicians’ Desk 
Reference, 2007).
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Risks of Masculinizing Hormone Therapy (FtM)
Likely increased risk:
Polycythemia
•	Masculinizing hormone therapy involving testosterone or other androgenic steroids increases the 
risk of polycythemia (hematocrit > 50%), particularly in patients with other risk factors.
•	Transdermal administration and adaptation of dosage may reduce this risk.
Weight gain/visceral fat
•	Masculinizing hormone therapy can result in modest weight gain, with an increase in visceral fat.
Possible increased risk:
Lipids 
•	Testosterone therapy decreases HDL, but variably affects LDL and triglycerides.
•	Supraphysiologic (beyond normal male range) serum levels of testosterone, often found with 
extended intramuscular dosing, may worsen lipid profiles, whereas transdermal administration 
appears to be more lipid neutral.
•	Patients with underlying polycystic ovarian syndrome or dyslipidemia may be at increased risk of 
worsening dyslipidemia with testosterone therapy.
Liver 
•	Transient elevations in liver enzymes may occur with testosterone therapy.
•	Hepatic dysfunction and malignancies have been noted with oral methyltestosterone. However, 
methyltestosterone is no longer available in most countries and should no longer be used.
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Psychiatric
Masculinizing therapy involving testosterone or other androgenic steroids may increase the risk of 
hypomanic, manic, or psychotic symptoms in patients with underlying psychiatric disorders that include 
such symptoms. This adverse event appears to be associated with higher doses or supraphysiologic 
blood levels of testosterone.
Inconclusive or no increased risk:
Items in this category include those that may present risk, but for which the evidence is so minimal that 
no clear conclusion can be reached. 
Osteoporosis
•	Testosterone therapy maintains or increases bone mineral density among FtM patients prior to 
oophorectomy, at least in the first three years of treatment.
•	There is an increased risk of bone density loss after oophorectomy, particularly if testosterone 
therapy is interrupted or insufficient. This includes patients utilizing solely oral testosterone.
Cardiovascular 
•	Masculinizing hormone therapy at normal physiologic doses does not appear to increase the risk 
of cardiovascular events among healthy patients.
•	Masculinizing hormone therapy may increase the risk of cardiovascular disease in patients with 
underlying risks factors.
Hypertension 
•	Masculinizing hormone therapy at normal physiologic doses may increase blood pressure but 
does not appear to increase the risk of hypertension.
•	Patients with risk factors for hypertension, such as weight gain, family history, or polycystic ovar-
ian syndrome, may be at increased risk.
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Type 2 diabetes mellitus
•	Testosterone therapy does not appear to increase the risk of type 2 diabetes among FtM patients 
unless other risk factors are present.
•	Testosterone therapy may further increase the risk of type 2 diabetes in patients with other risk 
factors, such as significant weight gain, family history, and polycystic ovarian syndrome. There are 
no data that suggest or show an increase in risk in those with risk factors for dyslipidemia.
Breast cancer
•	Testosterone therapy in FtM patients does not increase the risk of breast cancer. 
Cervical cancer
•	Testosterone therapy in FtM patients does not increase the risk of cervical cancer, although it may 
increase the risk of minimally abnormal Pap smears due to atrophic changes. 
Ovarian cancer
•	Analogous to persons born with female genitalia with elevated androgen levels, testosterone 
therapy in FtM patients may increase the risk of ovarian cancer, although evidence is limited.
Endometrial (uterine) cancer
•	Testosterone therapy in FtM patients may increase the risk of endometrial cancer, although evi-
dence is limited.
Other side effects of masculinizing therapy:
The following effects may be considered minor or even desired, depending on the patient, but are 
clearly associated with masculinization.
Fertility and sexual function
•	Testosterone therapy in FtM patients reduces fertility, although the degree and reversibility are 
unknown.
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•	Testosterone therapy can induce permanent anatomic changes in the developing embryo or fetus.
•	Testosterone therapy induces clitoral enlargement and increases libido.
Acne, androgenic alopecia
Acne and varying degrees of male pattern hair loss (androgenic alopecia) are common side effects of 
masculinizing hormone therapy.
APPENDIX C 
SUMMARY OF CRITERIA FOR HORMONE 
THERAPY AND SURGERIES 
As for all previous versions of the SOC, the criteria put forth in the SOC for hormone therapy and surgical 
treatments for gender dysphoria are clinical guidelines; individual health professionals and programs 
may modify them. Clinical departures from the SOC may come about because of a patient’s unique 
anatomic, social, or psychological situation; an experienced health professional’s evolving method of 
handling a common situation; a research protocol; lack of resources in various parts of the world; or the 
need for specific harm reduction strategies. These departures should be recognized as such, explained 
to the patient, and documented through informed consent for quality patient care and legal protection. 
This documentation is also valuable to accumulate new data, which can be retrospectively examined to 
allow for health care – and the SOC – to evolve.  
Criteria for Feminizing/Masculinizing Hormone Therapy (one 
referral or chart documentation of psychosocial assessment)
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC for children and adolescents);
4. If significant medical or mental concerns are present, they must be reasonably well controlled.
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Criteria for Breast/Chest Surgery (one referral)
Mastectomy and creation of a male chest in FtM patients:
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC for children and adolescents);
4. If significant medical or mental health concerns are present, they must be reasonably well con-
trolled.
Hormone therapy is not a pre-requisite.
Breast augmentation (implants/lipofilling) in MtF patients:
1. Persistent, well-documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country (if younger, follow the SOC for children and adolescents);
4. If significant medical or mental health concerns are present, they must be reasonably well 
controlled.
Although not an explicit criterion, it is recommended that MtF patients undergo feminizing hormone 
therapy (minimum 12 months) prior to breast augmentation surgery. The purpose is to maximize 
breast growth in order to obtain better surgical (aesthetic) results. 
Criteria for Genital Surgery (two referrals) 
Hysterectomy and ovariectomy in FtM patients and orchiectomy in MtF patients: 
1. Persistent, well documented gender dysphoria;
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2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country; 
4. If significant medical or mental health concerns are present, they must be well controlled;
5. 12 continuous months of hormone therapy as appropriate to the patient’s gender goals (unless 
the patient has a medical contraindication or is otherwise unable or unwilling to take hormones).
The aim of hormone therapy prior to gonadectomy is primarily to introduce a period of reversible 
estrogen or testosterone suppression, before a patient undergoes irreversible surgical intervention. 
These criteria do not apply to patients who are having these surgical procedures for medical indications 
other than gender dysphoria.
Metoidioplasty or phalloplasty in FtM patients and vaginoplasty in MtF patients: 
1. Persistent, well documented gender dysphoria;
2. Capacity to make a fully informed decision and to consent for treatment;
3. Age of majority in a given country; 
4. If significant medical or mental health concerns are present, they must be well controlled;
5. 12 continuous months of hormone therapy as appropriate to the patient’s gender goals (unless 
the patient has a medical contraindication or is otherwise unable or unwilling to take hormones);
6. 12 continuous months of living in a gender role that is congruent with their gender identity. 
Although not an explicit criterion, it is recommended that these patients also have regular visits with a 
mental health or other medical professional. 
The criterion noted above for some types of genital surgeries – i.e., that patients engage in 12 
continuous months of living in a gender role that is congruent with their gender identity – is based on 
expert clinical consensus that this experience provides ample opportunity for patients to experience 
and socially adjust in their desired gender role, before undergoing irreversible surgery.
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APPENDIX D 
EVIDENCE FOR CLINICAL OUTCOMES 
OF THERAPEUTIC APPROACHES 
One of the real supports for any new therapy is an outcome analysis. Because of the controversial 
nature of sex reassignment surgery, this type of analysis has been very important. Almost all of the 
outcome studies in this area have been retrospective. 
One of the first studies to examine the post-treatment psychosocial outcomes of transsexual patients 
was done in 1979 at Johns Hopkins University School of Medicine and Hospital (USA) (J. K. Meyer 
& Reter, 1979). This study focused on patients’ occupational, educational, marital, and domiciliary 
stability. The results revealed several significant changes with treatment. These changes were not seen 
as positive; rather, they showed that many individuals who had entered the treatment program were 
no better off or were worse off in many measures after participation in the program. These findings 
resulted in closure of the treatment program at that hospital/medical school (Abramowitz, 1986). 
Subsequently, a significant number of health professionals called for a standard for eligibility for sex 
reassignment surgery. This led to the formulation of the original Standards of Care of the Harry Benjamin 
International Gender Dysphoria Association (now WPATH) in 1979. 
In 1981, Pauly published results from a large retrospective study of people who had undergone 
sex reassignment surgery. Participants in that study had much better outcomes: Among 83 FtM 
patients, 80.7% had a satisfactory outcome (i.e., patient self report of “improved social and emotional 
adjustment”), 6.0% unsatisfactory. Among 283 MtF patients, 71.4% had a satisfactory outcome, 8.1% 
unsatisfactory. This study included patients who were treated before the publication and use of the 
Standards of Care.
Since the Standards of Care have been in place, there has been a steady increase in patient satisfaction 
and decrease in dissatisfaction with the outcome of sex reassignment surgery. Studies conducted after 
1996 focused on patients who were treated according to the Standards of Care. The findings of Rehman 
and colleagues (1999) and Krege and colleagues (2001) are typical of this body of work; none of the 
patients in these studies regretted having had surgery, and most reported being satisfied with the 
cosmetic and functional results of the surgery. Even patients who develop severe surgical complications 
seldom regret having undergone surgery. Quality of surgical results is one of the best predictors of the 
overall outcome of sex reassignment (Lawrence, 2003). The vast majority of follow-up studies have 
shown an undeniable beneficial effect of sex reassignment surgery on postoperative outcomes such 
as subjective well being, cosmesis, and sexual function (De Cuypere et al., 2005; Garaffa, Christopher, 
& Ralph, 2010; Klein & Gorzalka, 2009), although the specific magnitude of benefit is uncertain from 
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the currently available evidence. One study (Emory, Cole, Avery, Meyer, & Meyer III, 2003) even showed 
improvement in patient income. 
One troubling report (Newfield et al., 2006) documented lower scores on quality of life (measured 
with the SF-36) for FtM patients than for the general population. A weakness of that study is that it 
recruited its 384 participants by a general email rather than a systematic approach, and the degree 
and type of treatment was not recorded. Study participants who were taking testosterone had typically 
being doing so for less than 5 years. Reported quality of life was higher for patients who had undergone 
breast/chest surgery than for those who had not (p<.001). (A similar analysis was not done for genital 
surgery). In other work, Kuhn and colleagues (2009) used the King’s Health Questionnaire to assess 
the quality of life of 55 transsexual patients at 15 years after surgery. Scores were compared to those of 
20 healthy female control patients who had undergone abdominal/pelvic surgery in the past. Quality 
of life scores for transsexual patients were the same or better than those of control patients for some 
subscales (emotions, sleep, incontinence, symptom severity, and role limitation), but worse in other 
domains (general health, physical limitation, and personal limitation). 
It is difficult to determine the effectiveness of hormones alone in the relief of gender dysphoria. Most 
studies evaluating the effectiveness of masculinizing/feminizing hormone therapy on gender dysphoria 
have been conducted with patients who have also undergone sex reassignment surgery. Favorable 
effects of therapies that included both hormones and surgery were reported in a comprehensive review 
of over 2000 patients in 79 studies (mostly observational) conducted between 1961 and 1991 (Eldh, 
Berg, & Gustafsson, 1997; Gijs & Brewaeys, 2007; Murad et al., 2010; Pfäfflin & Junge, 1998). Patients 
operated on after 1986 did better than those before 1986; this reflects significant improvement in 
surgical complications (Eldh et al., 1997). Most patients have reported improved psychosocial 
outcomes, ranging between 87% for MtF patients and 97% for FtM patients (Green & Fleming, 1990). 
Similar improvements were found in a Swedish study in which “almost all patients were satisfied with 
sex reassignment at 5 years, and 86% were assessed by clinicians at follow-up as stable or improved in 
global functioning” (Johansson, Sundbom, Höjerback, & Bodlund, 2010). Weaknesses of these earlier 
studies are their retrospective design and use of different criteria to evaluate outcomes.
A prospective study conducted in the Netherlands evaluated 325 consecutive adult and adolescent 
subjects seeking sex reassignment (Smith, Van Goozen, Kuiper, & Cohen-Kettenis, 2005). Patients who 
underwent sex reassignment therapy (both hormonal and surgical intervention) showed improvements 
in their mean gender dysphoria scores, measured by the Utrecht Gender Dysphoria Scale. Scores for 
body dissatisfaction and psychological function also improved in most categories. Fewer than 2% 
of patients expressed regret after therapy. This is the largest prospective study to affirm the results 
from retrospective studies that a combination of hormone therapy and surgery improves gender 
dysphoria and other areas of psychosocial functioning. There is a need for further research on the 
effects of hormone therapy without surgery, and without the goal of maximum physical feminization 
or masculinization.
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Overall, studies have been reporting a steady improvement in outcomes as the field becomes more 
advanced. Outcome research has mainly focused on the outcome of sex reassignment surgery. In 
current practice there is a range of identity, role, and physical adaptations that could use additional 
follow-up or outcome research (Institute of Medicine, 2011).
APPENDIX E 
DEVELOPMENT PROCESS FOR THE 
STANDARDS OF CARE, VERSION 7
The process of developing Standards of Care, Version 7 began when an initial SOC “work group” 
was established in 2006. Members were invited to examine specific sections of SOC, Version 6. For 
each section, they were asked to review the relevant literature, identify where research was lacking 
and needed, and recommend potential revisions to the SOC as warranted by new evidence. Invited 
papers were submitted by the following authors: Aaron Devor, Walter Bockting, George Brown, Michael 
Brownstein, Peggy Cohen-Kettenis, Griet DeCuypere, Petra DeSutter, Jamie Feldman, Lin Fraser, Arlene 
Istar Lev, Stephen Levine, Walter Meyer, Heino Meyer-Bahlburg, Stan Monstrey, Loren Schechter, Mick 
van Trotsenburg, Sam Winter, and Ken Zucker. Some of these authors chose to add co-authors to assist 
them in their task.
Initial drafts of these papers were due June 1, 2007. Most were completed by September 2007, with 
the rest completed by the end of 2007. These manuscripts were then submitted to the International 
Journal of Transgenderism (IJT) . Each underwent the regular IJT peer review process. The final papers 
were published in Volume 11 (1-4) in 2009, making them available for discussion and debate. 
After these articles were published, an SOC Revision Committee was established by the WPATH Board 
of Directors in 2010. The Revision Committee was first charged with debating and discussing the IJT 
background papers through a Google website. A subgroup of the Revision Committee was appointed 
by the Board of Directors to serve as the Writing Group. This group was charged with preparing the first 
draft of SOC, Version 7 and continuing to work on revisions for consideration by the broader Revision 
Committee. The Board also appointed an International Advisory Group of transsexual, transgender, 
and gender nonconforming individuals to give input on the revision.
A technical writer was hired to (1) review all of the recommendations for revision – both the original 
recommendations as outlined in the IJT articles and additional recommendations that emanated from 
the online discussion – and (2) create a survey to solicit further input on these potential revisions. From 
the survey results, the Writing Group was able to discern where these experts stood in terms of areas 
of agreement and areas in need of more discussion and debate. The technical writer then (3) created a 
very rough first draft of SOC, Version 7 for the Writing Group to consider and build on.  
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The Writing Group met on March 4 and 5, 2011 in a face-to-face expert consultation meeting. They 
reviewed all recommended changes and debated and came to consensus on various controversial 
areas. Decisions were made based on the best available science and expert consensus. These decisions 
were incorporated into the draft, and additional sections were written by the Writing Group with the 
assistance of the technical writer. 
The draft that emerged from the consultation meeting was then circulated among the Writing Group 
and finalized with the help of the technical writer. Once this initial draft was finalized it was circulated 
among the broader SOC Revision Committee and the International Advisory Group. Discussion was 
opened up on the Google website and a conference call was held to resolve issues. Feedback from 
these groups was considered by the Writing Group, who then made further revision. Two additional 
drafts were created and posted on the Google website for consideration by the broader SOC Revision 
Committee and the International Advisory Group. Upon completion of these three iteratations of review 
and revision, the final document was presented to the WPATH Board of Directors for approval. The 
Board of Directors approved this version on September 14, 2011.  
Funding
The Standards of Care revision process was made possible through a generous grant from the Tawani 
Foundation and a gift from an anonymous donor. These funds supported the following: 
1. Costs of a professional technical writer;  
2. Process of soliciting international input on proposed changes from gender identity professionals 
and the transgender community; 
3. Working meeting of the Writing Group; 
4. Process of gathering additional feedback and arriving at final expert consensus from the pro-
fessional and transgender communities, the Standards of Care, Version 7 Revision Committee, and 
WPATH Board of Directors;
5. Costs of printing and distributing Standards of Care, Version 7 and posting a free downloadable 
copy on the WPATH website;
6. Plenary session to launch the Standards of Care, Version 7 at the 2011 WPATH Biennial Symposium 
in Atlanta, Georgia, USA.
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